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TREATMENT OF MCI AND ALZHEIMER'S 
DISEASE 
REFERENCE TO RELATED APPLICATION 
This application is a continuation-in-part of U.S. appli-
cation Ser. No. 12/779,345, filed on May 13, 2010, which 
claims the benefit of U.S. Provisional Patent Application No. 
61/216,452, filed May 15, 2009, and U.S. Provisional Patent 
Application No. 61/234,551, filed Aug. 17, 2009, both of 
which are hereby incorporated by reference in their entire-
ties. 
BACKGROUND OF THE INVENTION 
Alzheimer's disease (AD) is a well-known but incom-
pletely understood progressive neurodegenerative disease 
affecting ever-larger numbers of individuals in the aging 
population. Currently Alzheimer's disease affects 4 million 
Americans. Statistics from the National Institute on Aging 
estimate that there may be 14 million Americans with 
Alzheimer's disease by 2040 unless preventative strategies 
are developed. 
The earliest clinical manifestation of Alzheimer's disease 
is described as a syndrome called Mild Cognitive Impair-
ment (MCI). While detection of MCI may permit necessary 
lifestyle modifications to be planned and implemented, no 
therapies are currently available that forestall the progres-
sion of MCI to Alzheimer's disease or to treat Alzheimer's 
disease. 
In 2007 testimony before the US Senate, FDA Commis-
sioner Dr. Andrew C. von Eschenbach stated that "the 
estimated 4.5 million cases of Alzheimer's today can be 
expected to rise to about 16 million by 2050." Dr. Eschen-
bach explained that five drugs were approved for AD 
treatment-tacrine, rivastigmine, galantamine, donepezil, 
and memantine-the first four of which act by elevating 
acetylcholine levels in the brain, and the last of which is an 
antagonist of the N-methyl-D-aspartate receptor. Thus, Dr. 
Eschenbach pointed out that none of the five approved drugs 
have been shown to prevent or slow the underlying nerve 
degeneration in [AD] patients. He continued: "We await, 
together with the rest of the world, [ ] new drugs that may 
some day be able to treat the underlying cause of this 
insidious disease as well as other neurological 
diseases . . . .  " 
SUMMARY OF THE INVENTION 
The present invention encompasses the discovery that 
nifedipine and its oxidized or nitroso derivatives can effec-
tively inhibit A l-40 generation, reduce A  processing 
enzymes and inactivate related biochemical pathways, both 
in vitro and in vivo. More surprisingly, the present inventors 
discovered that a lactam (e.g., a compound of formula (le) 
or (le-i) such as NFD-Ll) can also effectively inhibit A  1-40 
generation, reduce A  processing enzymes and inactivate 
related biochemical pathways, both in vitro and in vivo. 
Without wishing to be bound by any theory, it is contem-
plated that nitroso-nifedipine may likely be a pro-drug that 
converts stoichiometrically into lactam once administered in 
vivo. Thus, the present invention provides, among other 
things, novel therapeutic methods and compositions, based 
on nifedipine and its oxidized or nitroso derivatives, and/or 
lactam and its derivatives ( e.g., a compound of formula (le) 
or (le-i), e.g., NFD-Ll), that can effectively treat, slow or 
2 
prevent Mild Cognitive Impairment (MCI) and/or Alzheim-
er's disease, as well as delaying the progression from MCI 
to AD. 
In one aspect, the present invention provides a pharma-
ceutical composition suitable for treating, slowing, or pre-
venting a neurological disease in a human subject compris-
ing a therapeutically effective amount of one or more 
therapeutic agents and a pharmaceutically acceptable carrier. 
In some embodiments, the neurological disease is a neuro-
10 degenerative disease. In some embodiments, the neurode-
generative disease is Mild Cognitive Impairment (MCI) 
and/or Alzheimer's disease. In some embodiments, a thera-
peutic agent is of formula (Ia) as defined and described 
herein. In some embodiments, a therapeutic agent is of 
15 formula (lb) as defined and described herein. In some 
embodiments, a therapeutic agent is of formula (le) as 
defined and described herein. In some embodiments, a 
therapeutic agent suitable for the invention is selected from 
the group consisting of nifedipine, oxidized nifedipine, 
20 nitroso-nifedipine, lactam (e.g., a compound of formula (le) 
or (le-i), e.g., NFD-Ll), thyroxine (T4), triiodothyronine 
(T3) and combinations thereof. In some embodiments, a 
therapeutic agent suitable for the invention is a calcium 
channel blocker. In some embodiments, a therapeutic agent 
25 suitable for the invention is not a calcium channel blocker. 
In some embodiments, a therapeutic agent suitable for the 
invention increases calcium influx. 
In some embodiments, a therapeutic agent suitable for the 
invention comprises nifedipine. In some embodiments, a 
30 therapeutic agent suitable for the invention comprises oxi-
dized nifedipine. In some embodiments, a therapeutic agent 
suitable for the invention comprises nitroso-nifedipine. In 
some embodiments, a therapeutic agent suitable for the 
invention comprises lactam ( e.g., a compound of formula 
35 (le) or (le-i), e.g., NFD-Ll). In some embodiments, a 
therapeutic agent suitable for the invention comprises a 
mixture of nitroso-nifedipine, oxidized nifedipine, and nife-
dipine. In some embodiments, a therapeutic agent suitable 
for the invention comprises a mixture of nitroso-nifedipine 
40 and lactam ( e.g., a compound of formula (le) or (le-i), e.g., 
NFD-Ll). In some embodiments, a therapeutic agent suit-
able for the invention comprises a mixture of lactam ( e.g., a 
compound of formula (le) or (le-i), e.g., NFD-Ll), oxidized 
nifedipine, and nifedipine. In some embodiments, a thera-
45 peutic agent suitable for the invention comprises 55% 
nitroso-nifedipine, 11 % oxidized nifedipine, and 34% nife-
dipine. In some embodiments, a therapeutic agent suitable 
for the invention comprises one or more (e.g., two, three, 
four) of lactam ( e.g., a compound of formula (le) or (le-i), 
50 e.g., NFD-Ll), nitroso-nifedipine, oxidized nifedipine, and 
nifedipine. In some embodiments, various therapeutic 
agents described herein further comprises thyroxine (T4) 
and/or triiodothyronine (T3). In some embodiments, a thera-
peutic agent suitable for the invention comprises nifedipine, 
55 oxidized nifedipine, nitroso-nifedipine, thyroxine (T4) and/ 
or triiodothyronine (T3). 
In some embodiments, a pharmaceutical composition 
according to the present invention comprises a therapeutic 
agent in a therapeutically effective amount of about 0.01 to 
60 about 1000 mg ( e.g., about 0.01 to about 200 mg, about 0.01 
to about 100 mg, about 0.1 to about 50 mg, about 0.01 to 
about 10 mg, about 0.01 to about 5 mg, about 0.01 to about 
2.5 mg, about 0.01 to about 2.0 mg, about 0.01 to about 1.5 
mg, about 0.01 to about 1.0 mg, about 0.01 to about 0.5 mg, 
65 about 0.01 to about 0.1 mg) per dose. In some embodiments, 
a pharmaceutical composition according to the present 
invention comprises nitroso-nifedipine in a therapeutically 
US 9,968,574 B2 
3 
effective amount of about 10 mg to 2.5 g ( e.g., about 10 mg 
to 2.0 g, about 10 mg to 1.5 g, about 10 to about 1000 mg, 
about 10 mg to about 500 mg) per dose. 
4 
In some embodiments, a therapeutically effective amount 
o f  an agent according to the present invention is sufficient to 
increase a glutamate transporter level in the brain of a human 
subject. In some embodiments, a glutamate transporter level 
is a glial glutamate transporter EAAT2 level. In some 
embodiments, a therapeutically effective amount of an agent 
according to the present invention is insufficient to induce an 
adverse event in a human subject. In some embodiments, an 
adverse event is liver toxicity. 
In some embodiments, a therapeutic agent used in a 
method according to the present invention is of formula (Ia) 
as defined and described herein. In some embodiments, a 
therapeutic agent used in a method according to the inven-
tion is o f  formula (lb) as defined and described herein. In 
In some embodiments, a pharmaceutical composition 
according to the present invention comprises a therapeutic 
agent in a therapeutically effective amount, wherein the 
therapeutically effective amount is insufficient to induce an 
adverse event in a human subject. In some embodiments, an 
adverse event is liver toxicity. In some embodiments, a 
pharmaceutical composition according to the present inven- 10 
tion comprises a therapeutic agent in a therapeutically 
effective amount, wherein the therapeutically effective 
amount is insufficient to induce an adverse event in a human 
subject, wherein the agent is nitroso-nifedipine and the 
adverse event is liver toxicity. 
15 some embodiments, a therapeutic agent used in a method 
according to the invention is o f  formula (le) as defined and 
described herein. In some embodiments, a suitable thera-
peutic agent is selected from the group consisting o f  nife-
dipine, oxidized nifedipine, nitroso-nifedipine, lactam (e.g., 
In some embodiments, a pharmaceutical composition 
according to the present invention is formulated for oral, 
subcutaneous, intravenous, transdermal, intraperitoneal, 
intramuscular, intracerebroventricular, intraparenchymal, 
intrathecal, intracranial, buccal, mucosa!, nasal, or rectal 
administration. In certain embodiments, a pharmaceutical 
composition according to the present invention is formulated 
for oral administration. In some embodiments, a pharma-
ceutical composition according to the invention is formu-
lated for immediate or extended release. 
In another aspect, the present invention provides a method 
for treating, slowing, or preventing a neurological disease in 
a human subject, the method comprising administering to 
the subject who is suffering from or susceptible to a neuro-
logical disease a therapeutic agent, such that at least one 
symptom or feature associated with the neurological disease 
is reduced in abundance, intensity, severity, or frequency, or 
has delayed onset. In some embodiments, a neurological 
disease is a neurodegenerative disorder. In some embodi-
ments, the present invention provides a method for treating, 
slowing, or preventing Mild Cognitive Impairment (MCI) 
and/or Alzheimer's disease in a human subject, the method 
comprising administering to a subject who is suffering from 
or susceptible to M C I  or Alzheimer's disease a therapeuti-
cally effective amount of one or more therapeutic agents, 
such that at least one symptom or feature associated with the 
M C I  or Alzheimer's disease is reduced in abundance, inten-
sity, severity, or frequency, or has delayed onset. In some 
embodiments, a symptom or feature is cognitive decline, 
production o f  amyloid beta protein, beta-secretase activity, 
gamma-secretase activity, paired helical filaments, phospho-
rylated tau protein in the brain, and/or an immune or 
inflammatory condition in the central nervous system. In 
some embodiments, an immune or inflannnatory condition 
in the central nervous system is viral meningitis, viral 
encephalitis, fungal meningitis, fungal encephalitis, multiple 
sclerosis, schizophrenia, myasthenia gravis, or charcot joint. 
20 a compound o f  formula (le) or (le-i), e.g., NFD-Ll),  thy-
roxine (T4), triiodothyronine (T3) and combinations thereof. 
In some embodiments, a suitable therapeutic agent is a 
calcium charmel blocker. In some embodiments, a suitable 
therapeutic agent is not a calcium channel blocker. In some 
25 embodiments, a suitable therapeutic agent increases calcium 
influx. 
In some embodiments, a suitable therapeutic agent com-
prises nifedipine. In some embodiments, a suitable thera-
peutic agent comprises oxidized nifedipine. In some 
30 embodiments, a suitable therapeutic agent comprises 
nitroso-nifedipine. In some embodiments, a suitable thera-
peutic agent comprises lactam ( e.g., a compound o f  formula 
(le) or (le-i), e.g., NFD-Ll).  In some embodiments, a 
suitable therapeutic agent used in a method according to the 
35 present invention comprises a mixture o f  nitroso-nifedipine, 
oxidized nifedipine, and nifedipine. In some embodiments, 
a suitable therapeutic agent comprises a mixture o f  nitroso-
nifedipine and lactam (e.g., a compound of formula (le) or 
(le-i), e.g., NFD-Ll).  In some embodiments, a suitable 
40 therapeutic agent comprises a mixture o f  lactam ( e.g., a 
compound o f  formula (le) or (le-i, e.g., NFD-Ll),  oxidized 
nifedipine, and nifedipine. In some embodiments, a suitable 
therapeutic agent used in a method according to the present 
invention comprises 55% nitroso-nifedipine, 11 % oxidized 
45 nifedipine, and 34% nifedipine. In some embodiments, a 
suitable therapeutic agent comprises one or more ( e.g., two, 
three, four) of lactam (e.g., a compound o f  formula (le) or 
(le-i), e.g., NFD-Ll  ), nitroso-nifedipine, oxidized nife-
dipine, and nifedipine. In some embodiments, suitable 
50 agents described herein further comprises T3/T4. In some 
embodiments, an suitable agent used in a method o f  the 
present invention comprising nifedipine, oxidized nife-
dipine, and/or nitroso-nifedipine further comprises thyrox-
In some embodiments, production o f  amyloid beta protein 
comprises production o f  A   1-40. In some embodiments, 55 
production o f  amyloid beta protein comprises production o f  
A   1-42. In some embodiments, production o f  amyloid beta 
protein is reduced by increasing an alpha-secretase activity. 
ine (T4) and/or triiodothyronine (T3). 
In some embodiments, a method according to the present 
invention administers to a subject in need o f  treatment a 
therapeutic agent in a therapeutically effective amount o f  
about 0.01 to about 1000 mg (e.g., about 0.01 to about 200 
mg, about 0.01 to about 100 mg, about 0.1 to about 50 mg, In some embodiments, alpha-secretase activity is A D A M - IO 
activity. In some embodiments, the gannna-secretase activ-
ity is reduced by inhibiting presenilin-1 (PS-1), nicastrin, 
APH-1 and/or PEN-2 activity. In some embodiments, the 
gamma-secretase activity is reduced by inhibiting orphan 
G-coupled receptor 3 (GPCR-3) activity. In some embodi-
ments, an immune or inflammatory condition is reduced by 
decreasing the level o f  one or more cytokines (e.g., IL-1,
IL-6, TNF-a) in the central nervous system. 
60 about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 
0.01 to about 2.5 mg, about 0.01 to about 2.0 mg, about 0.01 
to about 1.5 mg, about 0.01 to about 1.0 mg, about 0.01 to 
about 0.5 mg, about 0.01 to about 0.1 mg) per dose. In some 
embodiments, a method according to the present invention 
65 administers to a subject in need o f  treatment a therapeutic 
agent comprising nitroso-nifedipine in a therapeutically 
effective amount of about 10 mg to about 2.5 g (e.g., about 
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10 mg to about 2.0 g, about 10 mg to about 1.5 g, about 10 
mg to about 1000 mg, or about 10 mg to about 500 mg) per 
dose. In some embodiments, an agent used in a method 
according to the present invention is administered by oral, 
subcutaneous, intravenous, transdermal, intraperitoneal, 
intramuscular, intracerebroventricular, intraparenchymal, 
intrathecal, intracranial, buccal, mucosa!, nasal, or rectal 
administration. In certain embodiments, an agent used in a 
method according to the present invention is administered 
orally. 10 
In some embodiments, according to a method of the 
present invention, an agent is administered monthly, bi-
weekly, or weekly. In some embodiments, according to a 
method o f  the present invention, an agent is administered 
daily. In some embodiments, according to a method o f  the 15 
present invention, an agent is administered twice daily, three 
times daily, or four times daily. 
In some embodiments, a subject treated by a method o f  
the present invention has a diminished or elevated level o f  
a biomarker (e.g., a protein biomarker complex) as com- 20 
pared to a control. In some embodiments, a suitable bio-
marker is a protein biomarker complex comprising at least 
one o f  a transthyretin protein and/or a prostaglandin-H2 
D-isomerase protein, and at least one second, different 
protein selected from a transthyretin, prostaglandin-H2 25 
D-isomerase, beta-2-microglobulin, cystatin C ,  superoxide 
dismutase [ C u - Z n ] ,  plasma retinal-binding protein, phos-
phatidylethanolamine-binding protein, carbonic anhydrase 
2, and/or serotransferrin protein. In some embodiments, a 
suitable protein biomarker complex comprises prostaglan- 30 
din-D2-synthase and transthyretin (PDS/TTR complex). In 
some embodiments, a suitable biomarker comprises one or 
more o f  (i) beta amyloid 40 (A 40), (ii) beta amyloid 42 
(A 42), (iii) the ratio of A 40 to A 42, and (iv) the ratio o f
phosphorylated tau to total tau. In some embodiments, a 35 
biomarker is determined in a fluid sample ( e.g., CSF, serum, 
whole blood, blood plasma, urine, ascitic fluid, saliva, tissue 
effusion, lavage, and combinations thereof) obtained from 
the subject. In some embodiments, a suitable control is 
indicative o f  a level o f  the biomarker in a subject selected 40 
from the group consisting o f  a healthy individual, a patient 
suffering from Alzheimer's disease with a pre-determined 
stage, the subject before the treatment, and combinations 
thereof. 
In some embodiments, a subject to be treated has a test 45 
score indicative of cognitive impairment. In some embodi-
ments, a test score indicative o f  cognitive impairment is an 
M M S E  score (e.g., lower than 27, e.g., 21-26). In some 
embodiments, a test score indicative o f  cognitive impair-
ment is a C D R  score (e.g., above 0, e.g., 0.5, e.g., 1). 50 
In some embodiments, a method according to the inven-
tion further includes a step o f  first determining the thera-
peutically effective amount o f  the therapeutic agent based on 
the level o f  a biomarker and/or a cognitive test score. 
In yet another aspect, the invention provides a solid oral 55 
dosage form comprising nitroso-nifedipine and nifedipine, 
and wherein the mass ratio o f  nitroso-nifedipine to nife-
dipine is at least about 1: 1 ( e.g., at least about 2: 1, at least 
about 4:1, at least about 8:1, at least about 16:1, at least 
about 32:1, at least about 64:1, at least about 100:1, at least 60 
about 200:1, at least about 500:1, or at least about 1000:1). 
In some embodiments, a solid oral dosage form according to 
the present invention further comprises one or more phar-
maceutically acceptable excipients ( e.g., a binder, a buffer, a 
diluent, a dispersant, an emollient, a film-forming agent, a 65 
glidant, a light-blocking agent, a preservative, a solvent, a 
stabilizing agent, a surfactant, a suspending agent, and/or a 
6 
tonicity agent). In some embodiments, a solid dosage form 
is for controlled or extended release. In some embodiments, 
a solid dosage form is for immediate release. 
In yet another aspect, the invention provides benzo[ c ][2, 
7]naphthyridine-5(6H)-one compounds. In some embodi-
ments, provided compounds are o f  the general formula (le): 
O R1 
(le) 
or a pharmaceutically acceptable salt thereof, wherein: 
R 1 and R2 are independently an optionally substituted 
group selected from C 1_6 aliphatic, C 1_6 heteroaliphatic, aryl, 
heteroaryl, or cyano; 
R3 is an optionally substituted group selected from C 1_6 
aliphatic, C 1_6 heteroaliphatic or aryl; 
R s is halogen, optionally substituted C 1_6 aliphatic, 
hydroxyl, alkoxy, amino, alkylamino, cyano, nitro, or 
nitroso; and 
n is 0, 1, 2, or 3. 
In certain embodiments, provided compounds are o f  
formula (le-i): 
O R1 
(lc-i) 
or a pharmaceutically acceptable salt thereof, wherein: 
R 1 and R2 are independently C 1_6 aliphatic or cyano; 
R3 is C 1_6 aliphatic; 
R s is halogen, C 1_6 aliphatic, hydroxyl, alkoxy, amino, 
alkylamino, cyano, nitro, or nitroso; and 
n is 0, 1, 2, or 3. 
In certain embodiments, an inventive compound is NFD-
L l .  
Among other things, the present invention also provides 
pharmaceutical compositions containing a compound 
described herein (e.g., a compound of formula le or le-i) and 
methods o f  use. In some embodiments, the present invention 
provides a method o f  treating, slowing, or preventing a 
neurological disease in a human subject by administering to 
a subject who is suffering from or susceptible to a neuro-
logical disease a compound described herein ( e.g., such as a 
compound o f  formula le or le-i). In some embodiments, the 
present invention provides a method o f  treating, slowing, or 
preventing a neurodegenerative disease in a human subject 
by administering to a subject who is suffering from or 
susceptible to a neurodegenerative disease a compound 
described herein ( e.g., such as a compound o f  formula le or 
le-i). In some embodiments, the present invention provides 
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a method of treating, slowing, or preventing Mild Cognitive 
Impairment (MCI) and/or Alzheimer's disease in a human 
subject by administering to a subject who is suffering from 
or susceptible to MCI or Alzheimer's disease a compound 
described herein (e.g., such as a compound of formula le or 
le-i). In some embodiments, the invention provides a 
method of inhibiting beta secretase (BACE) in a human 
subject comprising administering to the human subject a 
compound described herein ( e.g., such as a compound of 
formula le or le-i). In some embodiments, the invention 10 
provides a method of modulating an inflanmiatory condition 
8 
FIG. 11 illustrates exemplary results indicating effect of 
nifedipine, nifedipine analogs and nifedipine mix, with and 
without T3/T4 on A 1_42 production from H4 cells. 
FIG. 12 illustrates exemplary results indicating effects of 
known calcium channel blockers such as Amilodpine, Dili-
tiazem, Felodipine, Isradipine, Nicardipine, and Nimodipine 
on A  1-42 generation in H4 neuroglioma cultures. 
FIG. 13 illustrates exemplary results indicating effects of 
NFD-Ll on A  1-42 generation in H4 neuroglioma cultures. 
FIG. 14 illustrates exempla r y  results indicating that 
nitroso-nifedipine significantly inhibits BACE activity. 
FIG. 15 illustrates exempla r y  results indicating that NFD-
Ll significantly inhibits BACE activity. in the central nervous system of a human subject by admin-
istering to the human subject a compound described herein 
(e.g., such as a compound of formula le or le-i). 
FIG. 16 illustrates exemplary results indicating the effect 
15 of nifedipine mix on PS-1, PEN-2, BACE-1 and Nicastrin, 
with and without T3/T4. In this application, the use of "or" means "and/or" unless 
stated otherwise. As used in this application, the term 
"comprise" and variations of the term, such as "comprising" 
and "comprises," are not intended to exclude other additives, 
components, integers or steps. As used in this application, 20 
the terms "about" and "approximately" are used as equiva-
lents. Any numerals used in this application with or without 
about/approximately are meant to cover any normal fluc-
tuations appreciated by one of ordinary skill in the relevant 
FIG. 17 illustrates exemplary results indicating the effect 
of nifedipine, nifedipine mix and/or T3/T4 on A l-40 
generation and certain A l-40 processing enzymes in a 
mouse model. 
FIG. 18 illustrates exemplary results indicating that treat-
ment with nitroso-nifedipine leads to a decrease in levels of 
A  1-40 in a mouse model. 
FIG. 19 illustrates exempla r y  results indicating that nife-
art. 
BRIEF DESCRIPTION OF THE DRAWINGS 
25 dipine, nifedipine mix and/or T3/T4 reduced GPCR-3 levels 
in H4 cultures or in mice treated acutely with drugs. The 
GPCR-3 levels were determined using Western blot analy-
sis. 
The drawings are for illustration purposes only and not for 
limitation. 
FIG. 1 illustrates an exemplary Western blot analysis of 
the PDS/TTR complex expressed in cell culture medium by 
control epithelial cells, control epithelial cells treated with 
acrolein, and late stage AD epithelial cells. 
FIG. 20 illustrates exemplary results indicating the effect 
30 of other classes of blood pressure drugs on the levels of 
GPCR-3 in H4 cultures with and without T3/T4. 
35 FIG. 2 illustrates exemplary survival data for cortical 
neurons treated with medium from control epithelial cells or 
AD epithelial cells. 
FIG. 3 illustrates exemplary results indicating that PHFl 
immunopositivity was detected in SY5Y cells resulting from 40 
exposure to the PDS/TTR protein complex. 
FIG. 4 illustrates exempla r y  Western blot data showing 
reduction of the PDS/TTR complex expressed by control 
epithelial cells treated with acrolein, acrolein plus T3/T4, 
acrolein plus nifedipine mixture (nitroso nifedipine 55%, 45 
oxidized nifedipine 11 % and nifedipine 34%) and acrolein 
plus nifedipine mix and T3/T4. 
FIG. 5 summarizes the numbers of PDS/TTR-positive 
cells determined by immunostaining in cultures treated with 
acrolein, acrolein plus T3/T4, acrolein plus nifedipine mix- 50 
ture (nitroso nifedipine 55%, oxidized nifedipine 11 % and 
nifedipine 34%) and acrolein plus nifedipine mix and T3/T4. 
FIG. 6 illustrates that nifedipine mix does not function as 
a calcium chamiel blocker compared to fresh nifedipine as 
determined by confocal microscopy and a calcium fluores- 55 
cent dye. 
FIG. 7 illustrates exemplary results indicating that inflam-
matory cytokine production was inhibited by nifedipine mix. 
FIG. 21 illustrates exempla r y  results showing survival of 
H4 cells after treatment with increasing concentrations of 
nitroso-nifedipine. 
FIG. 22 summarizes exemplary effects of nitroso-nife-
dipine on levels of enzymes involved in A  processing. 
FIG. 23 summarizes exempla r y  effects of NFD-Ll on 
levels of enzymes involved in A  processing. 
FIG. 24 summarizes exemplary effects of nitroso-nife-
dipine on levels of enzymes involved in A  processing in a 
mouse model. 
FIG. 25 summarizes exempla r y  effects of NFD-Ll on 
levels of enzymes involved in A  processing in a mouse 
model. 
FIG. 26 illustrates exemplary results indicating the effect 
of nifedipine, nifedipine mix and/or T3/T4 on the levels of 
enzymes involved in Tau phosphorylation measured in the 
mouse brains treated with corresponding compounds. 
FIG. 27 illustrates exempla r y  effects of nifedipine and 
nitroso-nifedipine on glutamate transporter levels. 
FIG. 28 illustrates exempla r y  results indicating that 
nitroso-nifedipine does not induce liver damage in mice. 
FIG. 29 illustrates exemplary trajectories fitted according 
to the NLMIXED model of MMSE verse age based on a 
human association study. 
FIG. 30 illustrates exemplary results indicating levels of 
A  1-42 and A  processing enzymes such as PS-1, Nicas, 
BACE, APH-1 and PEN-2 in front lobe specimens of 
subjects from a neuropsychological test score association FIG. 8 illustrates exemplary results indicating that inflam-
matory cytokine production was inhibited by NFD-Ll. 
FIG. 9 illustrates quantification of PHF-1 immunostaining 
for SY5Y cultures treated with medium from epithelial cells 
treated with acrolein and combinations of nifedipine, ana-
logs, mixtures and T3/T4. 
60 study who came to autopsy. 4 subjects were on calcium 
channel blockers, including nifedipine and 4 subjects were 
not on any calcium chamiel blocker. A  levels determined 
using Invitrogen ELISAs. Protein levels determined using 
FIG. 10 illustrates exempla r y  results indicating that 65 
A  1_42 generation is inhibited by nifedipine, oxidized nife-
dipine, nitroso nifedipine and T3/T4. 
Western blot analysis and antibodies specific to each protein. 
FIG. 31 illustrates exemplary results indicating enzyme 
levels involved in Tau phosphorylation in frontal lobe speci-
mens from the same subjects shown in FIG. 18. 
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FIG. 32 illustrates exemplary results indicating that treat-
ment o f  H4 neuroglioma cultures with nitroso-nifedipine 
leads to a sig n if icant increase in calcium influx as compared 
to control. 
FIG. 33 illustrates exemplary results from a photochemi-
cal synthesis o f  nitroso-nifedipine. 
FIG. 34 illustrates exempla r y  results from a synthesis o f  
NFD-Ll .  
10 
more different pharmaceutical agents are administered in 
overlapping regimens so that the subject is simultaneously 
exposed to both agents. 
Control: As used herein, the term "control" has its art-
understood meaning o f  being a standard against which 
results are compared. Typically, controls are used to aug-
ment integrity in experiments by isolating variables in order 
to make a conclusion about such variables. In some embodi-
ments, a control is a reaction or assay that is performed 
DEFINITIONS 
Unless defined otherwise, the scientific and technological 
terms and nomenclature used herein have the same meaning 
as commonly understood by a person of ordina r y  skill to 
which this invention pertains. Generally, the procedures o f  
cell cultures, infection, molecular biology methods and the 
like are common methods used in the art. Such standard 
techniques can be found in reference manuals such as, for 
example, Ausubel et al., Current Protocols in Molecular 
Biology, Wiley Interscience, New York, 2001; and Sam-
brook et al., Molecular Cloning: A Laboratory Manual, 3rd 
edition, Cold Spring Harbor Laboratory Press, N.Y., 2001. 
10 simultaneously with a test reaction or assay to provide a 
comparator. In one experiment, the "test" (i.e., the variable 
being tested) is applied. In the second experiment, the 
"control," the variable being tested is not applied. In some 
embodiments, a control is a historical control (i.e., o f  a test 
15 or assay performed previously, or an amount or result that is 
previously known). In some embodiments, a control is or 
comprises a printed or otherwise saved record. A control 
may be a positive control or a negative control. 
Dosing regimen: A "dosing regimen", as that term is used 
20 herein, refers to a set o f  unit doses (at least one and often 
more than one) that are administered individually separated 
by periods o f  time. The recommended set of doses (i.e., 
amounts, timing, route o f  administration, etc.) for a particu-
In order for the present invention to be more readily 
understood, certain terms are first defined. Additional defi- 25 
nitions for the following terms and other terms are set forth 
throughout the specification. 
Alzheimer's patient: A s  used herein, the terms "Alzheim-
er's patient," " A D  patient," and "individual diagnosed with 
A D "  all refer to an individual who has been diag n osed with 30 
A D  or has been given a probable diagnosis o f  Alzheimer's 
Disease (AD). 
Animal: As used herein, the term "animal" refers to any 
member of the animal kingdom. In some embodiments, 
"animal" refers to humans, at any stage o f  development. In 35 
some embodiments, "animal" refers to non-human animals, 
at any stage o f  development. In certain embodiments, the 
non-human animal is a mammal (e.g., a rodent, a mouse, a 
rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, 
and/or a pig). In some embodiments, animals include, but 40 
are not limited to, mannnals, birds, reptiles, amphibians, 
fish, insects, and/or worms. In some embodiments, an ani-
mal may be a transgenic animal, genetically-engineered 
animal, and/or a clone. 
lar therapeutic agent constitutes its dosing regimen. 
Functional: As used herein, a "functional" biological 
molecule is a biological molecule in a form in which it 
exhibits a property and/or activity by which it is character-
ized. 
Inhibition: As used herein, the terms "inhibition," 
"inhibit" and "inhibiting" refer to processes or methods o f  
decreasing or reducing activity and/or expression of a pro-
tein or a gene o f  interest. Typically, inhibiting a protein or a 
gene refers to reducing expression or a relevant activity o f  
the protein or gene by at least 10% or more, for example, 
20%, 30%, 40%, or 50%, 60%, 70%, 80%, 90% or more, or 
a decrease in expression or the relevant activity o f  greater 
than I-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 50-fold, 
100-fold or more as measured by one or more methods 
described herein or recog n ized in the art. 
In vitro: As used herein, the term "in vitro" refers to 
events that occur in an artificial environment, e.g., in a test 
tube or reaction vessel, in cell culture, etc., rather than within 
a multi-cellular organism. 
In vivo: As used herein, the term "in vivo" refers to events 
that occur within a multi-cellular organism such as a non-
human animal. 
Isolated: As used herein, the term "isolated" refers to a 
substance and/or entity that has been (1) separated from at 
least some o f  the components with which it was associated 
Approximately: As used herein, the term "approximately" 45 
or "about," as applied to one or more values o f  interest, 
refers to a value that is similar to a stated reference value. In 
certain embodiments, the term "approximately" or "about" 
refers to a range o f  values that fall within 25%, 20%, 19%, 
18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 
7%, 6%, 5%, 4%, 3%, 2%, 1 %, or less in either direction 
(greater than or less than) of the stated reference value unless 
otherwise stated or otherwise evident from the context 
50 when initially produced (whether in nature and/or in an 
experimental setting), and/or (2) produced, prepared, and/or 
manufactured by the hand o f  man. Isolated substances 
and/or entities may be separated from at least about 10%, 
about 20%, about 30%, about 40%, about 50%, about 60%, ( except where such number would exceed 100% o f  a pos-
sible value). 
Biological fluid sample: As used herein, the term "bio-
logical fluid sample" encompasses a variety of fluid sample 
types obtained from an individual and can be used in a 
diagnostic or monitoring assay. The term encompasses 
whole blood, blood serum or blood plasma, cerebrospinal 
fluid (CSF), urine and other liquid samples o f  biological 
origin. The term also includes samples that have been 
manipulated in any way after their procurement, such as by 
treatment with reagents, solubilization, or enrichment for 
certain components, such as proteins or polynucleotides. 
Combination therapy: The term "combination therapy", 
as used herein, refers to those situations in which two or 
55 about 70%, about 80%, about 90%, about 95%, about 98%, 
about 99%, substantially 100%, or 100% of the other 
components with which they were initially associated. In 
some embodiments, isolated agents are more than about 
80%, about 85%, about 90%, about 91%, about 92%, about 
60 93%, about 94%, about 95%, about 96%, about 97%, about 
98%, about 99%, substantially 100%, or 100% pure. As used 
herein, a substance is "pure" i f  it is substantially free o f  other 
components. As used herein, the term "isolated cell" refers 
65 
to a cell not contained in a multi-cellular organism. 
Individual with MCI: As used herein, "an individual with 
M C I  (mild cognitive impairment)" is typically an individual 
who meets the following clinical criteria o f  anmestic M C I  
US 9,968,574 B2 
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(Petersen et al. Arch Neural 56:303-308 (1999): 1) memory 
complaints corroborated by an informant, 2) objective 
memory impairment for age and education, 3) normal gen-
eral cognitive function, 4) intact activities o f  daily living, 
and 5) the subject does not meet criteria for dementia. 
Individual with EAD: As used herein, an "individual with 
E A D  (early or moderate Alzheimer's disease)" is an indi-
vidual who demonstrate the following criteria: 1) a decline 
in cognitive function for a previous higher level, 2) declines 
12 
25-30. A "Normal" individual is generally age-matched 
within a range o f  5 to 10 years, including but not limited to 
an individual that is age-matched, with the individual to be 
assessed. 
Protein: As used herein, the term "protein" refers to a 
polypeptide (i.e., a string o f  at least two amino acids linked 
to one another by peptide bonds). Proteins may include 
moieties other than amino acids ( e.g., may be glycoproteins, 
in one or more areas o f  cognition in addition to memory, 3) 10 
a clinical dementia rating scale score o f  0.5 to 1, and 4) a 
clinical examination that excluded other causes o f  dementia. 
proteoglycans, etc.) and/or may be otherwise processed or 
modified. Those o f  ordinary skill in the art will appreciate 
that a "protein" can be a complete polypeptide chain as 
produced by a cell (with or without a sig n al sequence), or 
can be a characteristic portion thereof. Those o f  ordinary 
skill will appreciate that a protein can sometimes include 
Individual with LAD: As used herein, an "individual with 
L A D  (severe or late stage Alzheimer's disease)" is an 
individual who meets the standard clinical diagnostic criteria 
for probable A D  (McKhann et al. Neurology 34:939-48 
(1984). 
Lactam: As used herein, a "lactam" is a cyclic amide. 
Typically, prefixes indicate how many carbon atoms (apart 
from the carbonyl moiety) are present in the ring:  -lactam 
(2 carbon atoms outside the carbonyl, 4 ring atoms in total), 
y-lactam (3 and 5), o-lactam (4 and 6). In some embodiment, 
a lactam suitable for the invention is defined by formula (le) 
or formula (Ic-i). In some embodiments, a lactam suitable 
for the invention is NFD-Ll .
Reference value: As used herein, a "reference value" can 
be an absolute value; a relative value; a value that has an 
upper and/or lower limit; a range o f  values; an average 
value; a median value, a mean value, or a value as compared 
to a particular control or baseline value. A reference value 
can be based on an individual sample value, such as for 
example, a value obtained from a sample from the individual 
with A D ,  M C I  or cognitive impairment, but at an earlier 
point in time, or a value obtained from a sample from an A D  
patient other than the individual being tested, or a "normal" 
individual, that is an individual not diagnosed with A D .  The 
reference value can be based on a large number o f  samples, 
such as from A D  patients or normal individuals or based on 
a pool of samples including or excluding the sample to be 
tested. 
Neurological disease: As used herein, the phrase "neuro-
logical disease" refers to a disease or disorder of the central 
nervous system. Neurological diseases include multiple 
sclerosis, neuropathies, and neurodegenerative disorders 
such as A D ,  Parkinson's disease, amyotrophic lateral scle-
rosis (ALS), Huntington's disease, mild cognitive impair-
ment (MCI) and frontotemporal dementia. Additional exem-
plary neurological diseases include epilepsy, convulsive 
disorder, pain, anxiety, depression, schizophrenia, post-an-
esthesia cog n itive decline, opioid tolerance, drug abuse, 
alcohol abuse, schizophrenia, neuroleptic malignant syn-
drome, Tourette's syndrome, Pick's Disease, dementia, 
delirium, neurodegeneration in Down Syndrome, Familial 
British Dementia, Familial Danish Dementia, Korsakoffs 
disease, olivopontocerebellar atrophy, HIV-induced demen-
tia and blindness, multi-infarct dementia, hereditary motor 
and sensory neuropathies (HMSN, also known as peroneal 
muscular atrophy or Charcot-Marie-Tooth disease), diabetic 
polyneuropathy, olivopontocerebellar atrophy, age-onset 
neurological deterioration, alcoholic polyneuropathy, tinni-
tus, and pathophysiologically symptomology. 
Normal individual: As used herein, a "Normal" individual 
15 more than one polypeptide chain, for example linked by one 
or more disulfide bonds or associated by other means. 
Polypeptides may contain L-amino acids, D-amino acids, or 
both and may contain any o f  a variety o f  amino acid 
modifications or analogs known in the art. Useful modifi-
20 cations include, e.g., terminal acetylation, amidation, etc. In 
some embodiments, proteins may comprise natural amino 
acids, non-natural amino acids, synthetic amino acids, and 
combinations thereof. The term "peptide" is generally used 
to refer to a polypeptide having a length o f  less than about 
25 100 amino acids. 
Subject: As used herein, the term "subject" or "patient" 
refers to any organism to which compositions in accordance 
with the invention may be administered, e.g., for experi-
mental, diag n ostic, prophylactic, and/or therapeutic pur-
30 poses. Typical subjects include animals ( e.g., mammals such 
as mice, rats, rabbits, non-human primates, and humans; 
insects; worms; etc.). 
Substantially: As used herein, the term "substantially" 
refers to the qualitative condition o f  exhibiting total or 
35 near-total extent or degree o f  a characteristic or property o f  
interest. One of ordinary skill in the biological arts will 
understand that biological and chemical phenomena rarely, 
i f  ever, go to completion and/or proceed to completeness or 
achieve or avoid an absolute result. The term "substantially" 
40 is therefore used herein to capture the potential lack o f  
completeness inherent in many biological and chemical 
phenomena. 
Suffering from: A n  individual who is "suffering from" a 
disease, disorder, and/or condition has been diagnosed with 
45 or displays one or more symptoms o f  the disease, disorder, 
and/or condition. 
Susceptible to: A n  individual who is "susceptible to" a 
disease, disorder, and/or condition has not been diagnosed 
with the disease, disorder, and/or condition. In some 
50 embodiments, an individual who is susceptible to a disease, 
disorder, and/or condition may not exhibit symptoms of the 
disease, disorder, and/or condition. In some embodiments, 
an individual who is susceptible to a disease, disorder, 
and/or condition will develop the disease, disorder, and/or 
55 condition. In some embodiments, an individual who is 
susceptible to a disease, disorder, and/or condition will not 
develop the disease, disorder, and/or condition. 
Therapeutically effective amount: As used herein, the 
term "therapeutically effective amount" o f  a therapeutic 
60 agent means an amount that is sufficient, when administered 
to a subject suffering from or susceptible to a disease, 
disorder, and/or condition, to treat, diagnose, prevent, and/or 
delay the onset o f  the symptom(s) o f  the disease, disorder, 
and/or condition. 
or "healthy" individual refers to an individual who has or 
would be assessed by a physician as not having A D  or MCI,  
and has an Mini-Mental State Examination (MMSE) (ref- 65 
erenced in Folstein et al., J .  Psychiatr. Res 1975; 12:1289-
198) score or would achieve a M M S E  score in the range o f
Therapeutic agent: As used herein, the phrase "therapeutic 
agent" refers to any agent that, when administered to a 
subject, has a therapeutic effect and/or elicits a desired 
US 9,968,574 B2 
13 
biological and/or pharmacological effect. As used herein, the 
terms "therapeutic agent" and "agent" are used inter-change-
ably. 
Treating: As used herein, the term "treat," "treatment," or 
"treating" refers to any method used to partially or com-
pletely alleviate, ameliorate, relieve, inhibit, prevent, delay 
onset of, reduce severity of and/or reduce incidence of one 
14 
carbon atoms. In still other embodiments, alkyl contains 1-3 
carbon atoms. In yet another embodiment, alkyl contains 1-2 
carbons. Examples of alkyl radicals include, but are not 
limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-
butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, 
neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, 
n-undecyl, dodecyl, and the like. 
Alkynyl: The term "alkynyl," as used herein, refers to a
monovalent group derived from a straight- or branched-
or more symptoms or features of a particular disease, 
disorder, and/or condition. Treatment may be administered 
to a subject who does not exhibit signs of a disease and/or 
exhibits only early signs of the disease for the purpose of 
decreasing the risk of developing pathology associated with 
the disease. 
10 chain aliphatic moiety having at least one carbon-carbon 
triple bond by the removal of a single hydrogen atom. In 
certain embodiments, alkynyl contains 2-6 carbon atoms. In 
certain embodiments, alkynyl contains 2-5 carbon atoms. In 
some embodiments, alkynyl contains 2-4 carbon atoms. In Definitions of specific functional groups and chemical 
terms are described in more detail below. For purposes of 
this invention, the chemical elements are identified in accor-
dance with the Periodic Table of the Elements, CAS version, 
Handbook o f  Chemistry and Physics, 75 th Ed., inside cover, 
and specific functional groups are generally defined as 
described therein. Additionally, general principles of organic 20 
chemistry, as well as specific functional moieties and reac-
tivity, are described in Organic Chemistry, Thomas Sorrell, 
University Science Books, Sausalito, 1999; Smith and 
March March's Advanced Organic Chemistry, 5th Edition, 
John Wiley & Sons, Inc., New York, 2001; Larock, Com- 25 
prehensive Organic Transformations, VCH Publishers, Inc., 
New York, 1989; Carruthers, Some Modern Methods o f  
Organic Synthesis, 3rd Edition, Cambridge University Press, 
Cambridge, 1987. 
15 another embodiment, alkynyl contains 2-3 carbon atoms. 
Representative alkynyl groups include, but are not limited 
to, ethynyl, 2-propynyl ("propargyl"), 1-propynyl, and the 
like. 
Amino: The term "amino," as used herein, refers to a 
group of the formula ( - N H2). 
Alkoxy: The term "alkoxy" refers to a "substituted 
hydroxyl" of the formula (-OR') ,  wherein R' is an alkyl 
group, as defined herein, and the oxygen moiety is directly 
attached to the parent molecule. 
Alkylamino: The term "alkylamino" refers to a "substi-
tuted amino" of the formula ( - N R \ ) ,  wherein Rh is, 
independently, a hydrogen or an alkyl group, as defined 
herein, and the nitrogen moiety is directly attached to the 
parent molecule. 
The compounds of the present invention may exist in 30 
particular geometric or stereoisomeric forms. The present 
invention contemplates all such compounds, including cis-
and trans-isomers, R- and S-enantiomers, diastereomers, 
(D)-isomers, (L)-isomers, the racemic mixtures thereof, and 
other mixtures thereof, as falling within the scope of the 35 
Aryl-As used herein, the term "aryl" refers to an option-
ally substituted monocyclic and bi cyclic ring systems having 
a total of five to 10 ring members, wherein at least one ring 
in the system is aromatic and wherein each ring in the 
system contains three to seven ring members. The term 
"aryl" may be used interchangeably with the term "aryl 
ring". In certain embodiments of the present invention, invention. 
"aryl" refers to an aromatic ring system which includes, but 
not limited to, phenyl, biphenyl, naphthyl, anthracyl and the 
like, which may bear one or more substituents. 
Cycloaliphatic: The terms "cycloaliphatic", "carbocycle", 
"carbocyclyl", "carbocyclo", or "carbocyclic", used alone or 
as part of a larger moiety, refer to a saturated or partially 
unsaturated cyclic aliphatic monocyclic or bicyclic ring 
systems, as described herein, having from 3 to 10 members, 
Aliphatic: The term "aliphatic" or "aliphatic group", as 
used herein, denotes a hydrocarbon moiety that may be 
straight-chain (i.e., unbranched), branched, or cycloaliphatic 
(including fused, bridging, and spiro-fused polycyclic) and 40 
may be completely saturated or may contain one or more 
units of unsaturation, but which is not aromatic. Unless 
otherwise specified, aliphatic groups contain 1-6 carbon 
atoms. In some embodiments, aliphatic groups contain 1-4 
carbon atoms, and in yet other embodiments aliphatic 
groups contain 1-3 carbon atoms. Suitable aliphatic groups 
include, but are not limited to, linear or branched, alkyl, 
alkenyl, and alkynyl groups, and hybrids thereof such as 
45 wherein the aliphatic ring system is optionally substituted as 
defined above and described herein. Cycloaliphatic groups 
include, without limitation, cyclopropyl, cyclobutyl, cyclo-
pentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohep-
tyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cycloocta-( cycloalkyl)alkyl, ( cycloalkenyl)alkyl or ( cycloalkyl)alk-
enyl. 
Alkenyl: The term "alkenyl," as used herein, denotes a 
monovalent group derived from a straight- or branched-
chain aliphatic moiety having at least one carbon-carbon 
double bond by the removal of a single hydrogen atom. In 
certain embodiments, alkenyl contains 2-6 carbon atoms. In 
certain embodiments, alkenyl contains 2-5 carbon atoms. In 
some embodiments, alkenyl contains 2-4 carbon atoms. In 
another embodiment, alkenyl contains 2-3 carbon atoms. 
Alkenyl groups include, for example, ethenyl ("vinyl"), 
propenyl ("ally!"), butenyl, l-methyl-2-buten-1-yl, and the 
like. 
Alkyl: The term "alkyl," as used herein, refers to a 
monovalent saturated, straight- or branched-chain hydrocar-
bon radical derived from an aliphatic moiety containing 
between one and six carbon atoms by removal of a single 
hydrogen atom. In some embodiments, alkyl contains 1-5 
carbon atoms. In another embodiment, alkyl contains 1-4 
50 dienyl. In some embodiments, the cycloalkyl has 3-6 
carbons. The terms "cycloaliphatic", "carbocycle", "carbo-
cyclyl", "carbocyclo", or "carbocyclic" also include ali-
phatic rings that are fused to one or more aromatic or 
nonaromatic rings, such as decahydronaphthyl, tetrahy-
55 dronaphthyl, decalin, or bicyclo[2.2.2]octane, where the 
radical or point of attachment is on an aliphatic ring. 
Cyano: The term "cyano," as used herein, refers to a 
group of the formula (----CN). 
Halogen: The terms "halo" and "halogen" as used herein 
60 refer to an atom selected from fluorine (fluoro, - F ) ,  chlo-
rine (chloro, - C l ) ,  bromine (bromo, - B r ) ,  and iodine 
(iodo, - I ) .  
Heteroaliphatic-As used herein, the terms "heteroali-
phatic" or "heteroaliphatic group", denote an optionally 
65 substituted hydrocarbon moiety having, in addition to car-
bon atoms, from one to five heteroatoms, that may be 
straight-chain (i.e., unbranched), branched, or cyclic ("het-
US 9,968,574 B2 
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erocyclic") and may be completely saturated or may contain 
one or more units ofunsaturation, but which is not aromatic. 
Unless otherwise specified, heteroaliphatic groups contain 
1-6 carbon atoms wherein 1-3 carbon atoms are optionally 
and independently replaced with heteroatoms selected from 5 
oxygen, nitrogen and sulfur. In some embodiments, heteroa-
liphatic groups contain 1-4 carbon atoms, wherein 1-2 
carbon atoms are optionally and independently replaced 
with heteroatoms selected from oxygen, nitrogen and sulfur. 
16 
heteroaryl, or carbocyclic rings, such as indolinyl, 3H-in-
dolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, 
where the radical or point of attachment is on the hetero-
cyclyl ring. A heterocyclyl group may be mono- or bicyclic. 
The term "heterocyclylalkyl" refers to an alkyl group sub-
stituted by a heterocyclyl, wherein the alkyl and heterocy-
clyl portions independently are optionally substituted. 
Nitro: The term "nitro," as used herein, refers to a group 
of the formula ( - N 02). 
Nitroso: The term "nitroso," as used herein, refers to a 
group of the formula (-NO). 
Partially unsaturated: As used herein, the term "partially 
unsaturated" refers to a ring moiety that includes at least one 
double or triple bond between ring atoms but is not aromatic. 
In yet other embodiments, heteroaliphatic groups contain 10 
1-3 carbon atoms, wherein 1 carbon atom is optionally and 
independently replaced with a heteroatom selected from 
oxygen, nitrogen and sulfur. Suitable heteroaliphatic groups 
include, but are not limited to, linear or branched, het-
eroalkyl, heteroalkenyl, and heteroalkynyl groups. 
Heteroaryl-As used herein, the term "heteroaryl" used 
alone or as part of a larger moiety, e.g., "heteroaralkyl", or 
"heteroaralkoxy", refers to an optionally substituted group 
having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; 
having 6, 10, or 14 it electrons shared in a cyclic array; and 20 
having, in addition to carbon atoms, from one to five 
heteroatoms. Heteroaryl groups include, without limitation, 
thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, 
tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, iso-
thiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, 25 
pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridi-
nyl. The terms "heteroaryl" and "heteroar-", as used herein, 
also include groups in which a heteroaromatic ring is fused 
15 The term "partially unsaturated" is intended to encompass 
rings having multiple sites of unsaturation, but is not 
intended to include aryl or heteroaryl moieties, as herein 
defined. 
Unsaturated: The term "unsaturated", as used herein, 
means that a moiety has one or more units of unsaturation. 
Optionally substituted-As described herein, compounds 
of the invention may contain "optionally substituted" moi-
eties. In general, the term "substituted", whether preceded 
by the term "optionally" or not, means that one or more 
hydrogens of the designated moiety are replaced with a 
suitable substituent. Unless otherwise indicated, an "option-
to one or more aryl, carbocyclic, or heterocyclic rings, where 
the radical or point of attachment is on the heteroaromatic 30 
ring. Non limiting examples include indolyl, isoindolyl, 
benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, ben-
zimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnoli-
nyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinoliz-
inyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, 35 
phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoqui-
nolinyl. A heteroaryl group may be mono- or bicyclic. The 
term "heteroaryl" may be used interchangeably with the 
terms "heteroaryl ring", "heteroaryl group", or "heteroaro-
matic", any of which terms include rings that are optionally 40 
substituted. 
ally substituted" group may have a suitable substituent at 
each substitutable position of the group, and when more than 
one position in any given structure may be substituted with 
more than one substituent selected from a specified group, 
the substituent may be either the same or different at every 
position. Combinations of substituents envisioned by this 
invention are preferably those that result in the formation of 
stable or chemically feasible compounds. The term "stable", 
as used herein, refers to compounds that are not substantially 
altered when subjected to conditions to allow for their 
production, detection, and, in certain embodiments, their 
recovery, purification, and use for one or more of the 
purposes disclosed herein. 
Suitable monovalent substituents on a substitutable car-
bon atom of an "optionally substituted" group are indepen-
dently halogen; - ( C H2)0_4R0; - ( C H2)0_40 R0; - O -
(CH2)0_4C(O)OR 0; - ( C H2)0_4CH(OR 
0)2; - ( C H2)0_4SR 0; 
- ( C H2)0_4Ph, which may be substituted with R0;
Heteroatom-As used herein, the term "heteroatom" 
refers to nitrogen, oxygen, or sulfur, and includes any 
oxidized form of nitrogen or sulfur, and any quatemized 
form of a basic nitrogen. The term "nitrogen" also includes 
a substituted nitrogen. 
Heterocyclic-As used herein, the terms "heterocycle", 
"heterocyclyl", "heterocyclic radical", and "heterocyclic 
ring" are used interchangeably and refer to a stable option-
ally substituted 5- to 7-membered monocyclic or 7- to 
10-membered bi cyclic heterocyclic moiety that is either 
saturated or partially unsaturated, and having, in addition to 
carbon atoms, one or more heteroatoms, as defined above. A 
heterocyclic ring can be attached to its pendant group at any 
heteroatom or carbon atom that results in a stable structure 
and any of the ring atoms can be optionally substituted. 
Examples of such saturated or partially unsaturated hetero-
cyclic radicals include, without limitation, tetrahydrofura-
nyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidi-
nyl, pyrrolinyl, tetrahydroquinolinyl, 
tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, 
piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, 
thiazepinyl, morpholinyl, and quinuclidinyl. The terms "het-
erocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic 
group", "heterocyclic moiety", and "heterocyclic radical", 
are used interchangeably herein, and also include groups in 
which a heterocyclyl ring is fused to one or more aryl, 
45 - ( C H2)0_40 (CH2)0_1Ph which may be substituted with R0; 
----CH=CHPh, which may be substituted with R0; - N 0 2; 
----CN; - N 3; - ( C H2)0_4N(R0)2; - ( C H2)0_4N(R0)C(O)R0; 
- N ( R  0)C(S)R 0; - ( C H2)0_4N(R 0)C(O)NR O 2; - N ( R  0C(S)
NR O 2; - ( C H2)0_4N(R 0)C(O)OR 0; - N ( R  0)N(R 0)C(O)R 0;
50 - N ( R  0)N(R 0)C(O)NR O 2; - N ( R  0)N(R 0)C(O)OR 0;
- ( C H2)0_4C(O)R0; ----C(S)R0; - ( C H2)0_4C(O)OR0;
- (  CH2)0_4 C(O )SRO; - (  CH2)0_4 C(O )OSiR O 3; - (  CH2)0_4
OC(O)R0; -OC(O)(CH2)0_4SR- , SC(S)SR0; - ( C H2)0_4
SC(O)R 0; - ( C H2)0_4C(O)NR O 2; ----C(S)NR O 2; ----C(S)SR 0;
55 -SC(S)SR0, - ( C H2)0_40 C(O)NR0 2; -C(O)N(OR0)R0; 
----C(O)C(O)R0; ----C(O)CH2C(O)R0; -C(NOR0)R0; 
- ( C H2)0_4SSR0; - ( C H2)0_4S(0 )2R0; - ( C H2)0_4S(0 )2
OR 0; - ( C H2)0_40 S(0 )2R 0; - S ( 0 )2NR 
O 
2; - ( C H2)0_4S(O)
R 0; - N ( R  0)S(0 )2NR O 2; - N ( R  0)S(0 )2R O 2; -N(OR 0)R 0;
60 ----C(NH)NR O 2; - P ( 0 )2R 0; -P(O)R O 2; ---OP(O)R O 2; 
---OP(O)(OR 0)2; SiR O 3; - ( C 1-4 straight or branched alky-
lene )O-N(R 0)2; or - ( C 1-4 straight or branched alkylene) 
C(O)O-N(R0)2, wherein each R0 may be substituted as 
defined below and is independently hydrogen, C1_6 aliphatic, 
65 ----CH2Ph, ---O(CH2)0_1Ph, or a 5-6-membered saturated, 
partially unsaturated, or aryl ring having 0-4 heteroatoms 
independently selected from nitrogen, oxygen, or sulfur, or, 
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notwithstanding the definition above, two independent 
occurrences of R0, taken together with their intervening 
atom(s), form a 3-12-membered saturated, partially unsatu-
rated, or aryl mono- or bicyclic ring having 0-4 heteroatoms 
independently selected from nitrogen, oxygen, or sulfur, 5 
which may be substituted as defined below. 
Suitable monovalent substituents on RO ( or the ring 
formed by taking two independent occurrences of RO 
together with their intervening atoms), are independently 
halogen, - ( C H2)0_2R• , -(haloR•), - ( C H2)0_20 H, 10 
- ( C H2)0_20 R • ,  - ( C H2)0_2CH(OR • )2; ---O(haloR •) ,
- C N ,  - N 3, - ( C H2)0-2CCO)R• , - ( C H2)0-2CCO)OH,
- ( C H2)0-2CCO)o R• , - ( C H2)0_2s R• , - ( C H2)0_2SH,
- ( C H2)0_2NH2, - ( C H2)0_2NHR • ,  - ( C H2)0_2NR • 2,
- N 0 2, - S i R •3, - O S i R •3, ----C(O)SR•, - ( C 1-4 straight 15 
or branched alkylene)C(O)OR•, or - S s R •  wherein each
R •  is unsubstituted or where preceded by "halo" is substi-
tuted only with one or more halogens, and is independently
selected from C1_4 aliphatic, ----CH2Ph, - O ( C H2)0_1 Ph, or a 
5-6-membered saturated, partially unsaturated, or aryl ring 20 
having 0-4 heteroatoms independently selected from nitro-
gen, oxygen, or sulfur. Suitable divalent substituents on a
saturated carbon atom of R0 include = 0  and = S .
Suitable divalent substituents on a saturated carbon atom 
of an "optionally substituted" group include the following: 25 
= 0 ,  = S ,  =NNR*2, NNHC(O)R*, NNHC(O)OR*, 
=NNHS(0)2R*, NR*, NOR*, - O ( C ( R \ ) )2_30 - , or 
- S ( C ( R  * 2))2_3S- , wherein each independent occurrence of
R * is selected from hydrogen, C1_6 aliphatic which may be
substituted as defined below, or an unsubstituted 5-6-mem- 30 
bered saturated, partially unsaturated, or aryl ring having 0-4 
heteroatoms independently selected from nitrogen, oxygen, 
or sulfur. Suitable divalent substituents that are bound to 
vicinal substitutable carbons of an "optionally substituted"
group include: ---O(CR * 2)2_30 - , wherein each indepen- 35 dent occurrence of R * is selected from hydrogen, C1_6 
aliphatic which may be substituted as defined below, or an
unsubstituted 5-6-membered saturated, partially unsatu-
rated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. 
Suitable substituents on the aliphatic group of R * include 40 
halogen, - R • ,  -(haloR•), - O H •  - O R • ,  ---O(haloR•J, 
- C N ,  ----C(O)OH, ----C(O)OR , - N H 2, - N H R  ,
- N R  • 2, or - N 0 2, wherein each R • is unsubstituted or
where preceded by "halo" is substituted only with one or
more halogens, and is independently C1_4 aliphatic, 45 
- C H 2Ph, ---O(CH2)0_1Ph, or a 5-6-membered saturated, 
partially unsaturated, or aryl ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. 
Suitable substituents on a substitutable nitrogen of an 
"optionally substituted" group include - R t , - N R \ ,  50 
-C(O)Rt ,  ----C(O)ORt , ----C(O)C(O)Rt , ----C(O)CH2C(O)
R \ - S ( 0 ) 2R\ - S(0 )2NRt 2, -C(S)NRt 2, -C(NH)NRt 2,
or - N ( Rt )S(0 )2R\ wherein each Rt is independently
hydrogen, C1_6 aliphatic which may be substituted as defined
below, unsubstituted ---OPh, or an unsubstituted 5-6-mem-
bered saturated, partially unsaturated, or aryl ring having 0-4 55 
heteroatoms independently selected from nitrogen, oxygen, 
or sulfur, or, notwithstanding the definition above, two
independent occurrences of Rt , taken together with their
intervening atom(s) form an unsubstituted 3-12-membered
saturated, partially unsaturated, or aryl mono- or bicyclic 60 
ring having 0-4 heteroatoms independently selected from 
nitrogen, oxygen, or sulfur. 
Suitable substituents on the aliphatic group of Rt are 
independently halogen, - R • ,  -(haloR•), - O H ,  - O R • ,  
-O(haloR•),  ----CN, -C(O)OH, -C(O)OR• ,  - N H 2, 65 
- N H R • ,  - N R • 2, or - N 0 2, wherein each R •  is unsub-
stituted or where preceded by "halo" is substituted only with
18 
one or more halogens, and is independently C1_4 aliphatic, 
----CH2Ph, ---O(CH2)0_1Ph, or a 5-6-membered saturated, 
partially unsaturated, or aryl ring having 0-4 heteroatoms 
independently selected from nitrogen, oxygen, or sulfur. 
DETAILED DESCRIPTION 
The present invention provides, among other things, 
therapeutic compositions and methods that can effectively 
treat, slow or prevent mild cognitive impairment (MCI) or 
Alzheimer's disease (AD). 
As described in the Examples section, the present inven-
tion is, in part, based on the following unexpected discov-
eries: (1) a protein complex PDS/TTR, known as a bio-
marker for early diagnosis of MCI or Alzheimer's disease, 
is neurotoxic and induces characteristic symptoms and fea-
tures of Alzheimer's disease in cell cultures; (2) dihydro-
pyridine calcium channel blockers (like nifedipine ), their 
oxidized, nitroso derivatives and mixtures (which no longer 
function as calcium channel blockers), and/or T3/T4 effec-
tively reduce or eliminate the ability of the PDS/TTR 
complex to induce AD-like symptoms and underlying 
enzymes and biochemical pathways in cell cultures and 
reduce endogenous levels of A  1-40 peptide in animal 
models; and (3) human association studies demonstrated that 
the use of dihydropyridine calcium channel blockers sig-
nificantly delays the onset of  cognitive decline thus indicat-
ing that these compounds may be used to effectively treat 
Alzheimer's disease. Surprisingly, the inventors found that 
oxidized, nitroso nifedipine derivatives and mixtures no 
longer function as calcium channel blockers. In some 
embodiments, nitroso nifedipine or a derivative thereof 
increases calcium influx. Without wishing to be bound by 
any theory, it is contemplated that the ability of these 
compounds to treat MCI or Alzheimer's disease may be 
independent of their ability to block calcium channels. 
More surprisingly, the present inventors discovered that 
lactam such as NFD-Ll can also effectively inhibit A  1-40 
generation, reduce A  processing enzymes and inactivate 
related biochemical pathways, both in vitro and in vivo, 
similar to nitroso-nifedipine. Without wishing to be bound 
by any theory, it is contemplated that nitroso-nifedipine may 
likely be a pro-drug that converts stoichiometrically into 
lactam once administered in vivo. 
Thus, the present invention contemplates methods and 
compositions that can effectively treat Alzheimer's disease 
based on therapeutically effective amount of nifedipine, 
oxidized or nitroso nifedipine derivatives, lactam (e.g., a 
compound of formula (le) or (le-i), e.g., NFD-Ll), thyroxine 
(T4), triiodothyronine (T3) and combinations thereof. In 
some embodiments, the present invention provides methods 
for treating, slowing, or preventing Mild Cognitive Impair-
ment (MCI) and/or Alzheimer's disease in a human subject, 
comprising administering to a subject who is suffering from 
or susceptible to MCI or Alzheimer's disease a therapeuti-
cally effective amount of an agent selected from the group 
consisting of nifedipine, oxidized nifedipine, nitroso-nife-
dipine, lactam (e.g., a compound of formula (le) or (le-i), 
e.g., NFD-Ll), thyroxine (T4), triiodothyronine (T3) and 
combinations thereof, such that at least one symptom or 
feature associated with the MCI or Alzheimer's disease is 
reduced in abundance, intensity, severity, or frequency, or 
has delayed onset. In some embodiments, the present inven-
tion contemplates methods and compositions that can effec-
tively treat Alzheimer's disease based on therapeutically 
effective amount of a compound of formula (Ia), (lb), (le), 
(II) and combinations thereof. In some embodiments, an 
agent suitable for the invention does not function as a
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calcium channel blocker. In some embodiments, an agent 
suitable for the invention increases calcium influx. 
It is further contemplated that inventive methods accord-
ing to the invention can be combined with sensitive bio-
markers and/or cognitive test scores to identify patents, 
including those at an early stage of the disease, for treatment 
and to monitor efficacy of the treatment. Thus, the present 
invention is particularly useful to treat early stage patients, 
especially, those patients having symptoms described as 
Mild Cognitive Impairment (MCI) and/or to prevent pro- 10 
gression of MCI to Alzheimer's disease. 
Various aspects of the invention are described in detail in 
the following sections. The use of sections is not meant to 
limit the invention. Each section can apply to any aspect of 15 
the invention. In this application, the use of "or" means 
"and/or" unless stated otherwise. 
Therapeutic Agents 
Therapeutic agents suitable for the present invention 
include both calcium channel blockers (e.g., dihydropyri- 20 
dine calcium channel blockers such as nifedipine) and 
non-calcium channel blockers ( e.g., oxidized nifedipine, 
nitroso-nifedipine, mixture of nifedipine and its derivatives, 
thyroxine (T4), triiodothyronine (T3)). 
In some embodiments, a therapeutic agent suitable for the 25 
present invention is of formula (Ia) or (lb): 
(la) 
30 
35 
(lb) 
40 
45 
20 
nitroso-nifedipine 
In some embodiments, therapeutic agents suitable for the 
present invention include, but are not limited to, dihydro-
pyridine compounds such as amlodipine, aranidipine, azel-
nidipine, bamidipine, benidipine, cilnidipine, clevidipine, 
efonidipine, felodipine, isradipine, lacidipine, manidipine, 
lercanidipine, nicardipine, nifedipine, nilvadipine, nimo-
dipine, nisoldipine, nitrendipine, and pranidipine. In some 
embodiments, therapeutic agents suitable for the present 
invention include, but are not limited to, oxidized amlo-
dipine, oxidized aranidipine, oxidized azelnidipine, oxidized 
barnidipine, oxidized benidipine, oxidized cilnidipine, oxi-
dized clevidipine, oxidized efonidipine, oxidized felodipine, 
oxidized isradipine, oxidized lacidipine, oxidized mani-
dipine, oxidized lercanidipine, oxidized nicardipine, oxi-
dized nifedipine, oxidized nilvadipine, oxidized nimodipine, 
oxidized nisoldipine, oxidized nitrendipine, and oxidized 
or a pharmaceutically acceptable salt thereof, wherein: 
R1 and R2 are independently C1_6 aliphatic or cyano; 
R3 and R4 are independently C1_6 aliphatic; 
R5 is halogen, C1_6 aliphatic, hydroxyl, alkoxy, amino, alky-
lamino, cyano, nitro, or nitroso; and 
50 pranidipine. It will be understood by one of ordinary skill in 
the art that an "oxidized" dihydropyridine compound (e.g., 
oxidized amlodipine, oxidized nimodipine, oxidized nival-
dipine) is the pyridine version of said compound. 
n is 0, 1, 2, or 3. 
In some embodiments, compounds of formula (Ia) are 
referred to as "reduced" or "dihydropyridines". In some 
embodiments, compounds of formula (lb) are referred to as 
"oxidized" or "dehydro". 
55 
In some embodiments, R1 and R2 are independently C1_3 60 
alkyl. In some embodiments, R3 and R4 are independently 
C1_4 alkyl. In some embodiments, R1 and R2 are methyl. In 
some embodiments, R3 and R4 are methyl. 
In some embodiments, a therapeutic agent suitable for the 
present invention is nifedipine, oxidized nifedipine, or 65 
nitroso-nifedipine. As used herein, "nitroso-nifedipine" is an 
oxidized analog of nifedipine, as shown below. 
nimodipine 
21 
-continued
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   Further exemplary therapeutic agents include the follow-
ing:
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wherein Z is H, F, Cl, Br, or l;
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wherein Z is H, F, Cl, Br, or I. 
In some embodiments, a therapeutic agent suitable for the 
present invention is o f  formula (le): 
O R1 
(le) 
or a pharmaceutically acceptable salt thereof, wherein: 
R 1 and R2 are independently an optionally substituted 
group selected from C 1_6 aliphatic, C 1_6 heteroaliphatic, aryl, 
heteroaryl, or cyano; 
R3 is an optionally substituted group selected from C 1_6 
aliphatic, C 1_6 heteroaliphatic or aryl; 
Rs is halogen, optionally substituted C 1_6 aliphatic, 
optionally substituted C 1_6 heteroaliphatic, hydroxyl, 
alkoxy, amino, alkylamino, cyano, nitro, or nitroso; and 
n is 0, 1, 2, or 3. 
In some embodiments, a therapeutic agent suitable for the 
present invention is o f  formula (le-i): 
O R1 
(lc-i) 
or a pharmaceutically acceptable salt thereof, wherein: 
R 1 and R2 are independently C 1_6 aliphatic or cyano; 
R3 is C 1_6 aliphatic; 
28 
As defined generally above, R 1 of formula (le) is an 
optionally substituted group selected from C 1_6 aliphatic, 
C 1_6 heteroaliphatic, aryl, heteroaryl, or cyano. In some 
embodiments, R 1 is substituted. In some embodiments, R 1 is 
unsubstituted. In some embodiments, R 1 is C 1_6 aliphatic. In 
some embodiments, R 1 is C 1_4 alkyl. In some embodiments, 
R 1 is methyl, ethyl, propyl, butyl, or isopropyl. In some 
embodiments, R 1 is methyl. In some embodiments, R 1 is 
10 isopropyl. In some embodiments, R 1 is cyano. In some 
embodiments, R 1 is C 1_6 heteroaliphatic. In some embodi-
ments, R 1 is ---OCH2C H2NH2 . In some embodiments, R
1 is 
aryl. In some embodiments, R 1 is heteroaryl. 
15 As defined generally above, R2 of formula (le) is an 
optionally substituted group selected from C 1_6 aliphatic, 
C 1_6 heteroaliphatic, aryl, heteroaryl, or cyano. In some 
embodiments, R2 is substituted. In some embodiments, R2 is 
20 unsubstituted. In some embodiments, R
2 is C 1_6 aliphatic. In 
some embodiments, R2 is C 1_4 alkyl. In some embodiments, 
R2 is methyl, ethyl, propyl, butyl, or isopropyl. In some 
embodiments, R2 is methyl. In some embodiments, R2 is 
isopropyl. In some embodiments, R2 is cyano. In some 
25 embodiments, R2 is C 1_6 heteroaliphatic. In some embodi-
ments, R2 is ---OCH2C H2NH2 . In some embodiments, R2 is 
aryl. In some embodiments, R2 is heteroaryl. 
In some embodiments, R 1 and R2 are independently C 1_3 
30 alkyl. In some embodiments, at least one o f  R 1 and R2 is 
methyl. In some embodiments, R 1 and R2 are methyl. 
As defined generally above, R3 of formula (le) is 
45 
60 nitroso. 
As defined generally above, n o f  formula (le) is 0, 1, 2, or 
Rs is halogen, C 1_6 aliphatic, hydroxyl, alkoxy, amino, 65 
alkylamino, cyano, nitro, or nitroso; and 
3. In some embodiments, n is 0. In some embodiments, n is 
1. In some embodiments, n is 2. In some embodiments, n is 
3. 
In some embodiments, a therapeutic agent suitable for the 
present invention is NFD-Ll .  n is 0, 1, 2, or 3. 
US 9,968,574 B2 
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(II) 
10 
NFD-Ll 
Further exempla r y  therapeutic agents include the follow-
ing: 15 
I
Y Y
X 
HO 
0 CN 
CN 
In some embodiments, a therapeutic agent suitable for the 
present invention is o f  formula (II): 
or a pharmaceutically acceptable salt thereof, wherein: 20 X is ----CH2- , - - - 0 - ,  or - N H - ;  and 
Y i s  - H o r - I .
In some embodiments, X i s  - C H 2- . In some embodi-
ments, X i s  - - - 0 - .  In some embodiments, X i s  - N H - .
In some embodiments, a therapeutic agent suitable for the 
25 present invention is thyroxine (T4) or triiodothyronine (T3): 
30 
35 
40 
45 
50 
55 
60 
In some embodiments, a therapeutic agent suitable for the 
present invention is a mixture of various compounds 
described herein. For example, two or more compounds o f  
formula (Ia) or (lb) can be combined to form a therapeutic 
65 agent. In some embodiments, two or more of nifedipine, 
oxidized nifedipine, and nitroso-nifedipine are combined. In 
some embodiments, T3 and/or T4 are combined with one or 
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more of nifedipine, oxidized nifedipine, and nitroso-nife-
dipine. In certain embodiments, nifedipine, oxidized nife-
dipine, and nitroso-nifedipine are combined to form a nife-
dipine mix or mixture. 
Compounds can be mixed at various mass or molar ratios. 5 
For example, a therapeutic agent according to the invention 
can be a mixture of two or more of nifedipine, oxidized 
nifedipine, nitroso-nifedipine, NFD-Ll, thyroxine (T4), and 
triiodothyronine (T3) at pre-determined mass or molar 
ratios. In some embodiments, a therapeutic agent suitable for 10 
the invention contains a mixture of nitroso-nifedipine and 
nifedipine. In some embodiments, nitroso-nifedipine and 
nifedipine can be mixed at a mass or molar ratio of about 
1000:1, about 500:1, about 200:1, about 100:1, about 64:1, 
about 32:1, about 16:1, about 10:1, about 8:1, about 5:1, 15 
about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, about 
1:3, about 1:4, about 1:5, about 1:8, about 1:10, about 1:16, 
about 1:32, about 1:64, about 1: 100, about 1:200, about 
1:500, or about 1:1000. In some embodiments, nitroso-
nefidipine and nifedipine can be mixed at a mass or molar 20 
ratio ranging from about 1: 1000 to about 1000: 1 (e.g., about 
1:500 to about 500:1, about 1:200 to about 200:1, about 
1:100 to about 100:1, about 1:10 to about 10:1, about 1:16 
to about 16:1, about 1:32 to about 32:1, about 1:64 to about 
64:1, about 1:1 to about 32:1, about 1:1 to about 10:1, about 25 
100:1 to about 1000:1, about 10:1 to about 100:1, about 
1: 1000 to 1: 1, about 1: 1 to about 1000: 1, or about 1: 100 to 
about 1: 10). In some embodiments, a therapeutic agent 
suitable for the invention contains a mixture of oxidized-
nifedipine and nifedipine. In some embodiments, oxidized- 30 
nifedipine and nifedipine can be mixed at a mass or molar 
ratio of about 1000: 1, about 500: 1, about 200: 1, about 100: 1, 
about 64:1, about 32:1, about 16:1, about 10:1, about 8:1, 
about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 
1:2, about 1:3, about 1:4, about 1:5, about 1:8, about 1:10, 35 
about 1: 16, about 1:32, about 1:64, about 1: 100, about 
1 :200, about 1 :500, or about 1: 1000. In some embodiments, 
oxidized-nefidipine and nifedipine can be mixed at a mass or 
molar ratio ranging from about 1: 1000 to about 1000:1 (e.g., 
about 1:500 to about 500:1, about 1:200 to about 200:1, 40 
about 1:100 to about 100:1, about 1:10 to about 10:1, about 
1:16 to about 16:1, about 1:32 to about 32:1, about 1:64 to 
about 64: 1, about 1: 1 to about 32: 1, about 1: 1 to about 10: 1, 
about 100:1 to about 1000:1, about 10:1 to about 100:1, 
about 1: 1000 to 1: 1, about 1: 1 to about 1000: 1, or about 45 
1:100 to about 1:10). In some embodiments, a therapeutic 
agent suitable for the invention contains a mixture of 
nitroso-nifedipine and oxidized nifedipine. In some embodi-
ments, nitroso-nifedipine and oxidized-nifedipine can be 
mixed at a mass or molar ratio of about 1000: 1, about 500: 1, 50 
about 200:1, about 100:1, about 64:1, about 32:1, about 
16:1, about 10:1, about 8:1, about 5:1, about 4:1, about 3:1, 
about 2: 1, about 1: 1, about 1:2, about 1:3, about 1:4, about 
1:5, about 1:8, about 1:10, about 1:16, about 1:32, about 
1:64, about 1:100, about 1:200, about 1:500, or about 55 
1:1000. In some embodiments, nitroso-nefidipine and oxi-
dized nifedipine can be mixed at a mass or molar ratio 
ranging from about 1: 1000 to about 1000: 1 ( e.g., about 
1:500 to about 500:1, about 1:200 to about 200:1, about 
1: 100 to about 100: 1, about 1: 10 to about 10: 1, about 1: 16 60 
to about 16:1, about 1:32 to about 32:1, about 1:64 to about 
64:1, about 1:1 to about 32:1, about 1:1 to about 10:1, about 
100:1 to about 1000:1, about 10:1 to about 100:1, about 
1: 1000 to 1: 1, about 1: 1 to about 1000: 1, or about 1: 100 to 
about 1: 10). In some embodiments, a therapeutic agent 65 
suitable for the invention contains a mixture of nitroso-
nifedipine, oxidized nifedipine, and nifedipine. In some 
32 
embodiments, nitroso-nifedipine, oxidized nifedipine, and 
nifedipine are mixed at a mass or molar ratio of about 5: 1:3, 
5:2:2, 6:3:1, 10:4:1, 3:1:5, 2:5:5, or 1:1:1. In some embodi-
ments, a therapeutic agent contains a mixture ofT3 and T4. 
In some embodiments, T3 and T 4 can be mixed at a mass or 
molar ratio of about 1000: 1, about 500: 1, about 200: 1, about 
100:1, about 64:1, about 32:1, about 16:1, about 10:1, about 
8:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, 
about 1:2, about 1:3, about 1:4, about 1:5, about 1:8, about 
1: 10, about 1: 16, about 1:32, about 1:64, about 1: 100, about 
1 :200, about 1 :500, or about 1: 1000. In some embodiments, 
T3 and T4 can be mixed at a mass or molar ratio ranging 
from about 1: 1000 to about 1000: 1 ( e.g., about 1:500 to 
about 500: 1, about 1 :200 to about 200: 1, about 1: 100 to 
about 100:1, about 1:10 to about 10:1, about 1:16 to about 
16:1, about 1:32 to about 32:1, about 1:64 to about 64:1, 
about 1: 1 to about 32: 1, about 1: 1 to about 10: 1, about 100: 1 
to about 1000:1, about 10:1 to about 100:1, about 1:1000 to 
1: 1, about 1: 1 to about 1000: 1, or about 1: 100 to about 1: 10). 
In some embodiments, various compounds and mixtures 
described herein can be further combined to generate desir-
able therapeutic agents for the invention. For example, a 
T3/T4 mix can be combined with any of the nifedipine, 
nifedipine derivatives ( e.g., oxidized or nitroso-nifedipine) 
or nifedipine mixtures described herein. 
In some embodiments, a therapeutic agent suitable for the 
invention comprises a mixture of nitroso-nifedipine and 
lactam (e.g., a compound of formula (le) or (le-i) such as 
NFD-Ll). In some embodiments, nitroso-nifedipine and 
lactam (e.g., a compound of formula (le) or (le-i) such as 
NFD-Ll) can be mixed at a mass or molar ratio of about 
1000: 1, about 500: 1, about 200: 1, about 100: 1, about 64: 1, 
about 32:1, about 16:1, about 10:1, about 8:1, about 5:1, 
about 4: 1, about 3: 1, about 2: 1, about 1: 1, about 1:2, about 
1:3, about 1:4, about 1:5, about 1:8, about 1: 10, about 1: 16, 
about 1:32, about 1:64, about 1: 100, about 1:200, about 
1:500, or about 1:1000. In some embodiments, nitroso-
nefidipine and lactam ( e.g., a compound of formula (le) or 
(le-i) such as NFD-Ll) can be mixed at a mass or molar ratio 
ranging from about 1: 1000 to about 1000: 1 ( e.g., about 
1:500 to about 500:1, about 1:200 to about 200:1, about 
1:100 to about 100:1, about 1:10 to about 10:1, about 1:16 
to about 16:1, about 1:32 to about 32:1, about 1:64 to about 
64:1, about 1:1 to about 32:1, about 1:1 to about 10:1, about 
100: 1 to about 1000: 1, about 10: 1 to about 100: 1, about 
1: 1000 to 1: 1, about 1: 1 to about 1000: 1, or about 1: 100 to 
about 1:10). In some embodiments, a therapeutic agent 
suitable for the invention contains a mixture of lactam ( e.g., 
a compound of formula (le) or (le-i) such as NFD-Ll) and 
oxidized nifedipine. In some embodiments, lactam (e.g., a 
compound of formula (le) or (le-i) such as NFD-Ll) and 
oxidized-nifedipine can be mixed at a mass or molar ratio of 
about 1000: 1, about 500: 1, about 200: 1, about 100: 1, about 
64:1, about 32:1, about 16:1, about 10:1, about 8:1, about 
5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, 
about 1:3, about 1 :4, about 1:5, about 1:8, about 1: 10, about 
1: 16, about 1:32, about 1:64, about 1: 100, about 1:200, 
about 1:500, or about 1:1000. In some embodiments, lactam 
(e.g., a compound of formula (le) or (le-i) such as NFD-Ll) 
and oxidized nifedipine can be mixed at a mass or molar 
ratio ranging from about 1: 1000 to about 1000: 1 (e.g., about 
1:500 to about 500:1, about 1:200 to about 200:1, about 
1:100 to about 100:1, about 1:10 to about 10:1, about 1:16 
to about 16:1, about 1:32 to about 32:1, about 1:64 to about 
64:1, about 1:1 to about 32:1, about 1:1 to about 10:1, about 
100: 1 to about 1000: 1, about 10: 1 to about 100: 1, about 
1: 1000 to 1: 1, about 1: 1 to about 1000: 1, or about 1: 100 to 
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about 1: 10). In some embodiments, a therapeutic agent 
suitable for the invention contains a mixture of lactam ( e.g., 
a compound of formula (le) or (le-i) such as NFD-Ll), 
oxidized nifedipine, and nifedipine. In some embodiments, 
lactam (e.g., a compound of formula (le) or (le-i) such as 5 
NFD-Ll), oxidized nifedipine, and nifedipine are mixed at 
a mass or molar ratio of about 5:1:3, 5:2:2, 6:3:1, 10:4:1, 
3:1:5, 2:5:5, or 1:1:1. In some embodiments, a therapeutic 
agent contains a mixture of T3 and T4. In some embodi-
ments, T3 and T4 can be mixed at a mass or molar ratio of 10 
about 1000: 1, about 500: 1, about 200: 1, about 100: 1, about 
64:1, about 32:1, about 16:1, about 10:1, about 8:1, about 
5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, 
about 1:3, about 1:4, about 1:5, about 1:8, about 1:10, about 
1:16, about 1:32, about 1:64, about 1:100, about 1:200, 15 
about 1:500, or about 1:1000. In some embodiments, T3 and 
T 4 can be mixed at a mass or molar ratio ranging from about 
1:1000 to about 1000:1 (e.g., about 1:500 to about 500:1, 
about 1:200 to about 200:1, about 1:100 to about 100:1, 
about 1:10 to about 10:1, about 1:16 to about 16:1, about 20 
1:32 to about 32:1, about 1:64 to about 64:1, about 1:1 to 
about 32:1, about 1:1 to about 10:1, about 100:1 to about 
1000: 1, about 10: 1 to about 100: 1, about 1: 1000 to 1: 1, 
about 1:1 to about 1000:1, or about 1:100 to about 1:10). In 
some embodiments, various compounds and mixtures 25 
described herein can be further combined to generate desir-
able therapeutic agents for the invention. For example, a 
T3/T4 mix can be combined with any of the nifedipine, 
nifedipine derivatives ( e.g., oxidized or nitroso-nifedipine ), 
compound of formula (I-c) (e.g., NFD-Ll, or nifedipine 30 
mixtures described herein. 
Biomarkers for Identifying Patients or Monitoring Treat-
ment 
Various biomarkers can be used to identify subject or 
patient who is suffering from, susceptible to or at risk of 35 
MCI or Alzheimer's disease. As used herein, a biomarker is 
a characteristic bio-molecule which is differentially present 
in a sample taken from a subject of one phenotypic status 
(e.g., having a disease) as compared with another pheno-
typic status ( e.g., not having a disease). A biomarker is 40 
differentially present between different phenotypic statuses 
if the mean or median expression level of the biomarker in 
the different groups is calculated to be statistically signifi-
cant. Biomarkers, alone or in combination, provide mea-
sures of relative risk that a subject belongs to one phenotypic 45 
status or another. Therefore, they are useful as markers for 
disease (diagnostics), therapeutic effectiveness of a drug 
(theranostics) and drug toxicity. 
For example, the inventors have recently shown that 
levels of a -55 kDa proteinaceous complex containing 50 
prostaglandin-D2-synthase and transthyretin (PDS/TTR 
complex) may serve as a sensitive and specific diagnostic 
biomarker of MCI and AD, as detailed in US Pat. Pub. No. 
2008/0026405, which is incorporated herein by reference. 
Typically, the PDS/TTR complex presents in cerebrospi- 55 
nal fluid and appears to be a sensitive and specific biomarker 
of the disease. Formation of the PDS/TTR complex was 
been localized to the choroid plexus, an assembly of epi-
thelial cells located adjacent to the lateral ventricles. The 
choroid plexus functions as the blood-CSP barrier. The 60 
choroid plexus passes water, salts and selected small mol-
ecules from the blood to the CSF but effectively prevents 
blood proteins form entering the CSF. Proteins required for 
CSF are synthesized by the choroid plexus. Thus, the 
choroid plexus also functions as the source of CSF. Epithe- 65 
lial cells isolated from choroid plexus obtained fresh from 
short post mortem autopsies of late stage AD patients have 
34 
been grown and expanded in culture. Examination of cell 
culture medium obtained from AD epithelial cells showed 
elevated levels of the PDS/TTR complex compared to 
control cells. Thus, an elevated PDS/TTR complex level as 
compared to a normal control can be used to identify 
subjects or patients suffering from, susceptible to or at risk 
of developing MCI or Alzheimer's disease. 
In some embodiments, a biomarker suitable for the pres-
ent invention comprises at least one of transthyretin and/or 
a prostaglandin-H2 D-isomerase, and at least one second 
protein selected from transthyretin, prostaglandin-H2 
D-isomerase, beta-2-microglobulin, cystatin C, superoxide 
dismutase [Cu-Zn], plasma retinal-binding protein, phos-
phatidylethanolamine-binding protein, carbonic anhydrase 2 
and/or serotransferrin. Mild cognitive impairment or 
Alzheimer's disease status is determined by correlating the 
obtained measurement with standards. 
In some embodiments, neuronal thread protein, tau (total; 
T-tau and various phosphorylated forms; P-tau), and/or 
derivatives of amyloid precursor protein (APP) including 
A 40 and A 42, may be used as biomarkers to identify 
patient population for treatment with compositions and 
methods of the present invention. In some embodiments, a 
subject in need of treatment has an abnormal level of a 
protein biomarker complex as compared to a control, 
wherein the protein biomarker complex comprises one or 
more of (i) beta amyloid 40 (A 40), (ii) beta amyloid 42 
(A 42), (iii) the ratio of A 40 to A 42, and (iv) the ratio of 
phosphorylated tau to total tau. 
Additional biomarkers have been reported in the literature 
and may be used to identify patients for treatment according 
to the invention including, but not limited to, those described 
in Fahnestock et al, J. Neural. Transm. Suppl. 2002(62): 
241-52 (2002); Masliah et al, Neurobiol. Aging 16(4):549-
56 (1995); Power et al, Dement. Geriatr. Cong. Disord. 
12(2):167-170 (2001); Burbach et al, J. Neurosci. 24(10): 
2421-30 (2004), Li et al, Neuroscience 113(3):607-15 
(2002), and Sanna et al, J. Clin. Invest. 111(2):241-50 
(2003), each of which is incorporated herein by reference. 
In some embodiments, a biomarker is determined in a 
fluid sample obtained from the subject. In some embodi-
ments, a fluid sample is selected from the group consisting 
of CSF, serum, whole blood, blood plasma, urine, ascitic 
fluid, saliva, tissue effusion, lavage, and combinations 
thereof. 
Various methods can be used to measure biomarkers 
qualitatively and quantitatively. For example, to detect a 
protein complex (such as PDS/TTR), a sandwich enzyme 
linked immunoassay (ELISA) cane be utilized that traps a 
first component of the complex (e.g., PDS) and probes for a 
second component (e.g. TTR). Additional exemplary meth-
ods are described in US Pat. Pub. No. 2008/0026405, which 
is incorporated herein by reference. Other methods are well 
known in the art and can be used to practice the present 
invention. 
Typically, the measured level of a biomarker is compared 
to one or more controls or reference levels. Suitable refer-
ence level used for comparison with the measured level for 
a AD biomarker may vary, depending on aspect of the 
invention being practiced, as will be understood by one of 
ordinary skill in the art. To identify subjects suffering from 
or susceptible to AD or MCI, a suitable "reference level" is 
typically a level indicative of healthy individuals, in par-
ticular, age-matched healthy individuals. A reference level 
can be determined in parallel with patient sample. A refer-
ence level can also be a pre-determined level or based on 
historical data. For example, a suitable reference level can 
US 9,968,574 B2 
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be an average oflevels obtained from a population that is not 
afflicted with A D  or MCI. Typically, a suitable reference 
level is derived from ( e.g., is the mean or median of) levels 
obtained from an age-matched population. 
Typically, a subject in need of treatment has an greater or 
elevated level o f  a biomarker described herein as compared 
to a control or reference level indicative o f  a healthy 
individual or population. 
36 
measurement techniques, and the mode of comparing a 
measured value and a reference value can vary depending on 
the measurement technology employed. For example, the 
measured values used in the methods o f  the invention will 
most commonly be quantitative values (e.g., quantitative 
measurements o f  concentration, such as nanograms of A D  
biomarker per milliliter o f  sample, or absolute amount). As 
with qualitative measurements, the comparison can be made 
by inspecting the numerical data, by inspecting representa-For treatment monitoring purposes, a suitable reference 
level is typically a level indicative o f  healthy individuals or 
individuals suffering from Alzheimer's disease ( e.g., with a 
pre-determined stage, such as MCI,  EAD,  or LAD). A 
reference level can be determined in parallel with patient 
sample. A reference level can also be a pre-determined level 
or based on historical data. For example, a suitable reference 
level can be an average of levels obtained from a population 
that is not afflicted with A D  or MCI, or a population that has 
been diagnosed with M C I  or A D  (e.g., E A D  or LAD). 
Alternately, a suitable reference level may be a historical 
reference level for a particular patient, for example, a level 
that was obtained from a sample derived from the same 
individual, but at an earlier point in time ( e.g., before the 
treatment or an earlier point in the treatment). Typically, a 
suitable reference level is derived from (e.g., is the mean or 
median of) levels obtained from an age-matched population. 
10 tions of the data (e.g., inspecting graphical representations 
such as bar or line graphs). As a non-limiting example, a 
measured value is generally considered to be substantially 
equal to or greater than a reference value i f  it is at least about 
95% o f  the value o f  the reference value (e.g., a measured 
15 value o f  1.71 can be considered substantially equal to a 
reference value o f  1.80). A measured value is considered less 
or lower than a reference value i f  the measured value is less 
than 95% o f  the reference value ( e.g., a measured value o f  
1.7 can be considered less than a reference value o f  1.80). 
20 Tests of Cognitive Function 
Various cognitive tests may also be used to identify 
subject or patient who is suffering from, susceptible to or at 
risk o f  M C I  or Alzheimer's disease. Two exempla r y  cogni-
tive tests are the Mini Mental Status Examination (MMSE) 
For A D  patient stratification (i.e., methods of stratifying 
A D  patients into mild, moderate and severe stages o f  AD), 
suitable reference levels are normally derived from ( e.g., is 
the mean or median of) levels obtained from a population 
which has been diagnosed with a particular stage of A D  
(e.g., E A D  or LAD) or MCI. 
25 and the Clinical Dementia Rating (CDR). 
In some embodiments, an M M S E  score is used to identify 
a subject in need o f  treatment with the compositions and 
methods described herein. A n  M M S E  score is a composite 
score representing multiple tests o f  cognitive function. The 
In some embodiments, the level of a suitable biomarker 
(such as the -55 kDa PDS/TTR complex) can be used to 
monitor the efficacy o f  the treatment. Typically, the goal o f  
30 maximum possible total M M S E  score is 30 points. The 
M M S E  can be used to classify the severity of cognitive 
impairment in patients with dementia or other medical 
conditions. Table 1 shows how M M S E  scores generally 
a therapy would be, ideally, to decrease, lower or diminish 35 
the level o f  the PDS/TTR complex in a subject so that a fluid 
sample taken from the subject would contain no detectable 
complex. A more conservative, subsidi a r y, goal of therapy 
would be to forestall any increase in the level o f  the -55 kDa 
PDS/TTR complex. Accordingly, a person o f  ordina r y  skill 40 
in the medical therapeutic arts would be able to determine 
whether a given therapeutic regime is accomplishing the 
chosen therapeutic goal based on the level o f  an appropriate 
biomarker. In this way, a person o f  ordina r y  skill in the 
medical therapeutic arts would also be able to determine the 45 
effective amount of a therapeutic agent described herein 
based on the measured level o f  a suitable biomarker as 
compared to appropriate controls or reference levels. 
Typically, aged-matched populations are used to derive 
various reference levels. Age-matched populations are ide- 50 
ally the same age as the individual being tested, but approxi-
mately age-matched populations are also acceptable. 
Approximately age-matched populations may be within 1, 2, 
3, 4, or 5 years o f  the age o f  the individual tested, or may be 
groups of different ages which encompass the age of the 55 
individual being tested. Approximately age-matched popu-
lations may be in 2, 3, 4, 5, 6, 7, 8, 9, or 10 year increments 
(e.g. a "5 year increment" group which serves as the source 
for reference values for a 62 year old individual might 
include 58-62 year old individuals, 59-63 year old individu- 60 
als, 60-64 year old individuals, 61-65 year old individuals, 
or 62-66 year old individuals). 
The process o f  comparing a measured value and a refer-
ence value can be carried out in any convenient manner 
appropriate to the type of measured value and reference 65 
value for the A D  biomarker at issue. For example, "mea-
suring" can be performed using quantitative or qualitative 
represent degrees o f  cognitive function. 
MMSE Score 
27-30 
21-26 
11-20 
0-10 
TABLE 1 
Cognitive Function 
normal cognitive function 
mild cognitive impairment 
moderate cognitive impairment 
severe cognitive impairment 
In some embodiments, a subject in need of treatment has 
an M M S E  score of 21-26 (mild cognitive impairment), 
11-20 (moderate cognitive impairment), or 0-10 (severe 
cognitive impairment). 
In some embodiments, a C D R  score is used to identify a 
subject in need o f  treatment with the compositions and 
methods described herein. A n  C D R  score is constructed 
from six domains that are scored individually: memory, 
orientation, judg m ent and problem solving, community 
affairs, home and hobbies, and personal care. Table 2 shows 
how C D R  scores generally represent degrees o f  cognitive 
function. 
MMSE Score 
0
0.5
2 
TABLE 2 
Cognitive Function 
no cognitive impairment 
very mild dementia 
mild dementia 
moderate dementia 
severe dementia 
In some embodiments, a C D R  score above O indicates that 
a subject may be suffering from, susceptible to or at risk o f  
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MCI or Alzheimer's disease. In some embodiments, a sub-
ject in need of treatment may have a CDR score of0.5 (very 
mild dementia), 1 (mild dementia), 2 (moderate dementia), 
or 3 (severe dementia). 
In some embodiments, a cognitive test score (such as an 
MMSE score or CDR score) can be used to monitor the 
efficacy of the treatment. Typically, an effective therapy 
should improve the cognitive test score. Therefore, by 
comparing the cognitive test scores before and after the 
treatment or from different time points of a treatment regi-
men, a person of ordinary skill in the medical therapeutic 
arts can determine whether a given therapeutic regime is 
effective. For example, a person of ordinary skill in the 
medical therapeutic arts would be able to determine or adjust 
the effective amount of a therapeutic agent described herein 
by based on relative cognitive test scores determined before 
the treatment or from different time points of a treatment 
regimen. 
Pharmaceutical Compositions and Administration 
The present invention encompasses pharmaceutical com-
positions comprising therapeutic agents such as those dis-
closed herein. In some embodiments, a pharmaceutical 
composition of the invention contain a therapeutically effec-
tive amount of a therapeutic agent and a pharmaceutically 
acceptable carrier. 
As used herein, the term "pharmaceutically acceptable 
carrier" means a non-toxic, inert solid, semi-solid liquid 
filler, diluent, encapsulating material, formulation auxilia r y
of any type, or simply a sterile aqueous medium, such as 
saline. Some examples of the materials that can serve as 
pharmaceutically acceptable carriers are sugars, such as 
lactose, glucose and sucrose, starches such as com starch 
and potato starch, cellulose and its derivatives such as 
sodium carboxymethyl cellulose, ethyl cellulose and cellu-
lose acetate; powdered tragacanth; malt, gelatin, talc; excipi-
ents such as cocoa butter and suppository waxes; oils such 
as peanut oil, cottonseed oil, safflower oil, sesame oil, olive 
oil, com oil and soybean oil; glycols, such as propylene 
glycol, polyols such as glycerin, sorbitol, mannitol and 
polyethylene glycol; esters such as ethyl oleate and ethyl 
laurate, agar; buffering agents such as magnesium hydroxide 
and aluminum hydroxide; alginic acid; pyrogen-free water; 
isotonic saline, Ringer's solution; ethyl alcohol and phos-
phate buffer solutions, as well as other non-toxic compatible 
substances used in pharmaceutical formulations. 
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as delay in progression of one or more symptoms of MCI or 
Alzheimer's disease (e.g., delay in progression with respect 
to abundance, intensity, severity, or frequency). It will be 
understood, however, that the total daily usage of the thera-
peutic agents and compositions of the present invention will 
be decided by the attending physician within the scope of 
sound medical judgment. The specific therapeutically effec-
tive dose level for any particular patient will depend upon a 
variety of factors including the disorder being treated and 
10 the severity of the disorder; activity of the specific com-
pound employed; the specific composition employed; the 
age, body weight, general health, sex and diet of the patient; 
the time of administration, route of administration, and rate 
of excretion of the specific compound employed; the dura-
15 tion of the treatment; drugs used in combination or coincid-
ing with the specific compound employed; and like factors 
well known in the medical arts. 
In some embodiments, a therapeutically effective dose of 
a therapeutic agent of the present invention can range, for 
20 example, from 0.01 to 100 mg/kg body weight or more. In 
some embodiments, a therapeutically effective dose of a 
therapeutic agent of the present invention ranges from about 
0.1 to about 50 mg/kg body weight (e.g., about 0.1 to about 
35 mg/kg, about 0.1 to about 15 mg/kg, about 6.25 to about 
25 35 mg/kg, about 12.5 to about 35 mg/kg, about 6.25 to about 
25 mg/kg, about 35 mg/kg). In some embodiments, a thera-
peutically effective amount of a therapeutic agent ranges 
from about 0.01 mg to about 2.5 g per dose ( e.g., from about 
0.01 mg to about 2.0 g, from about 0.01 mg to about 1.5 g, 
30 from about 0.01 mg to about 1.0 g, per dose). In some 
embodiments, a therapeutically effective amount of a thera-
peutic agent ranges from about 0.01 to about 1000 mg (e.g., 
about 0.01 to about 500 mg, about 0.01 to about 250 mg, 
about 0.01 to about 200 mg, about 0.01 to about 150 mg, 
35 about 0.01 to about 100 mg, about 0.01 to about 50 mg, 
about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 
0.01 to about 2.5 mg, about 0.01 to about 2.0 mg, about 0.01 
to about 1.5 mg, about 0.01 to about 1.0 mg, about 0.01 to 
about 0.5 mg, about 0.01 to about 0.1 mg) per dose. In some 
40 embodiments, the therapeutically effective amount of a 
therapeutic agent (in particular, nitroso-nifedipine) ranges 
from about 100 mg to about 5 g (e.g., about 100 mg to about 
3 g, about 100 mg to about 2.5 g, about 100 mg to about 2 
g, about 100 mg to about 1.5 g, about 100 mg to about 1000 
45 mg, about 100 mg to about 500 mg, about 100 mg to about 
250 mg) per dose. In some embodiments, a therapeutically 
effective amount of a therapeutic agent can be about 0.01 
mg, about 0.05 mg, about 0.1 mg, about 0.5 mg, about 1 mg, 
about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 
Wetting agents, emulsifiers and lubricants such as sodium 
lauryl sulfate and magnesium stearate, as well as coloring 
agents, releasing agents, coating agents, sweetening, flavor-
ing and perfuming agents, preservatives and antioxidants 
can also be present in the composition, according to the 
judgment of the formulator. Examples of pharmaceutically 
acceptable antioxidants include, but are not limited to, water 
soluble antioxidants such as ascorbic acid, cysteine hydro-
chloride, sodium bisulfite, sodium metabisulfite, sodium 
sulfite, and the like; oil soluble antioxidants, such as ascor- 55 
by! palmitate, butylated hydroxyanisole (BHA), butylated 
hydroxytoluene (BHT), lecithin, propyl gallate, alpha-to-
copherol and the like; and the metal chelating agents such as 
citric acid, ethylenediamine tetraacetic acid (EDTA), sorbi-
tol, tartaric acid, phosphoric acid and the like. 
50 100 mg, about 500 mg, about 1000 mg, about 1.5 g, about 
2 g, about 2.5 g, about 3 g, or about 5 g per dose. Typically, 
the amount described herein is the total amount of all active 
compounds in a composition. For example, if a composition 
contains a mix of nifedipine, nitroso-nifedipine and oxidized 
nifedipine, a therapeutically effective amount is the com-
bined amount ofnifedipine, nitroso-nifedipine and oxidized 
nifedipine. 
In some embodiments, a therapeutically effective amount 
of a therapeutic agent as described herein is an amount 
60 insufficient to induce an adverse event ( e.g., liver toxicity) in 
a human subject. The term "therapeutically effective amount" or simply 
"effective amount" of a therapeutic agent, as used herein, 
refers to an amount of therapeutic agent that is sufficient, 
when administered to a subject in need of treatment accord-
ing to an appropriate regimen, to alleviate, ameliorate, 65 
stabilize, and/or delay the onset of at least one symptom or 
feature associated with MCI or Alzheimer's disease as well 
In some embodiments, a therapeutic agent as described 
herein is administered once daily. In some embodiments, a 
therapeutic agent as described herein is administered mul-
tiple times per day, e.g., twice, three times, or four times 
daily. In some embodiments, a total daily dose of a thera-
peutic agent ranges from about 0.01 mg to about 5 g per day 
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in multiple doses or in a single dose (e.g., from about 0.01 
mg to about 4.0 g, from about 0.01 mg to about 3.0 g, from 
about 0.01 mg to about 2.5 g, from about 0.01 mg to about 
2.0 g, from about 0.01 mg to about 1.5 g, from about 0.01 
mg to about 1.0 g, per day in multiple doses or in a single 
dose). In some embodiments, a total daily dose o f  a thera-
peutic agent ranges from about 0.01 to about 1000 mg (e.g., 
about 0.01 to about 500 mg, about 0.01 to about 250 mg, 
about 0.01 to about 200 mg, about 0.01 to about 150 mg, 
about 0.01 to about 100 mg, about 0.01 to about 50 mg, 10 
about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 
0.01 to about 2.5 mg, about 0.01 to about 2.0 mg, about 0.01 
to about 1.5 mg, about 0.01 to about 1.0 mg, about 0.01 to 
about 0.5 mg, about 0.01 to about 0.1 mg) per day in a single 
dose or in multiple doses. In some embodiments, a total 15 
daily dose o f  a therapeutic agent (in particular, nitroso-
nifedipine) ranges from about 50 mg to about 5 g ( e.g., about 
50 mg to about 4 g, about 100 mg to about 3 g, about 100 
mg to about 2.5 g, about 100 mg to about 2 g, about 100 mg 
to about 1.5 g, about 100 mg to about 1000 mg, about 100 20 
mg to about 500 mg, about 100 mg to about 250 mg) per day 
in a single dose or in multiple doses. In some embodiments, 
a total daily dose o f  a therapeutic agent can be about 0.01 
mg, about 0.05 mg, about 0.1 mg, about 0.5 mg, about 1 mg, 
about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 25 
100 mg, about 500 mg, about 1000 mg, about 1.5 g, about 
2 g, about 2.5 g, about 3 g, about 3.5 g, about 4 g, about 4.5 
g, or about 5 g. Typically, an amount described herein is the 
total amount o f  all active compounds in a composition. For 
example, i f  a composition contains a mix o f  nifedipine, 30 
nitroso-nifedipine and oxidized nifedipine, a therapeutically 
effective amount is the combined amount o f  nifedipine, 
nitroso-nifedipine and oxidized nifedipine. 
In some embodiments, a therapeutic agent as described 
herein is administered monthly, bi-weekly, weekly, twice a 35 
week, or three times a week. In these instances, the daily 
doses described above reflects the average daily dose. 
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intratesticular, intrathecal, intrathroacic, intratubular, intra-
tumor, intratympanic, intrauterine, intravascular, intrave-
nous bolus, intravenous drip, intraventricular, intravesical, 
intravitreal, iontophoresis, irrigation, la r yngeal, nasogastric, 
occlusive dressing technique, ophthalmic, oropharyngeal, 
parenteral, percutaneous, peridural, perineum!, periodontal, 
respiratory, retrobulbar, soft tissue, subarachnoid, subcon-
junctival, sublingual, submucosal, topical, transdermal, 
transmucosal, transplacental, transtracheal, transtympanic, 
ureteral, urethral, and vaginal. In certain embodiments, a 
pharmaceutical composition o f  the present invention is 
administered by a route selected from oral, subcutaneous, 
intravenous, transdermal, intraperitoneal, intramuscular, 
intracerebroventricular, intraparenchymal, intrathecal, 
intracranial, buccal, mucosa!, nasal, and rectal. In certain 
embodiments, a pharmaceutical composition o f  the present 
invention is administered orally. 
Liquid dosage forms for oral administration may include 
pharmaceutically acceptable emulsions, microemulsions, 
solutions, suspensions, syrups and elixirs containing inert 
diluents commonly used in the art, such as water, isotonic 
solutions, or saline. Such compositions may also comprise 
adjuvants, such as wetting agents; emulsifying and suspend-
ing agents; sweetening, flavoring and perfuming agents. 
Injectable preparations, for example, sterile injectable 
aqueous or oleaginous suspensions may be formulated 
according to the known art using suitable dispersing or 
wetting agents and suspending agents. The sterile injectable 
preparation may also be a sterile injectable solution, sus-
pension or emulsion in a nontoxic parenterally acceptable 
diluent or solvent, for example, as a solution in 1,3-butane-
diol. Among the acceptable vehicles and solvents that may 
be employed are water, Ringer's solution, U.S.P. and iso-
tonic sodium chloride solution. In addition, sterile, fixed oils 
are conventionally employed as a solvent or suspending 
medium. For this purpose any bland fixed oil can be 
employed including synthetic mono- or diglycerides. In 
addition, fatty acids such as oleic acid are used in the 
preparation o f  injectables. 
The injectable formulation can be sterilized, for example, 
by filtration through a bacteria-retaining filter, or by incor-
porating sterilizing agents in the form of sterile solid com-
positions, which can be dissolved or dispersed in sterile 
In certain situations, it may be important to maintain a 
fairly high dose of the active agent in the blood stream o f  the 
patient, particularly early in the treatment. Hence, at least 40 
initially, it may be important to keep the dose relatively high 
and/or at a substantially constant level for a given period o f  
time, e.g., at least about six or more hours, e.g., at least about 
twelve or more hour, e.g., at least about twenty-four or more 
hours. 45 water or other sterile injectable medium just prior to use. 
The compounds of the present invention may be admin-
istered alone or in combination or in concurrent therapy with 
other agents which affect the central or peripheral nervous 
system, particularly selected areas o f  the brain. 
In order to prolong the effect o f  a drug, it is often desirable 
to slow the absorption o f  a drug from subcutaneous or 
intramuscular injection. The most common way to accom-
plish this is to inject a suspension o f  crystalline or amor-
50 phous material with poor water solubility. The rate o f  
absorption o f  the drug becomes dependent on the rate o f  
dissolution o f  the drug, which is, in turn, dependent on the 
physical state of the drug, for example, the crystal size and 
the crystalline form. Another approach to delaying absorp-
Pharmaceutical compositions according to the present 
invention may be administered by any route, including oral, 
subcutaneous, intravenous, intraperitoneal, intramuscular, 
intracerebroventricular, intraparenchymal, intrathecal, 
intracranial, buccal, mucosa!, nasal, rectal, auricular, con-
junctiva!, cutaneous, electro-osmosis, endocervical, endosi-
nusial, endotracheal, enteral, epidural, extra-amniotic, extra-
corporeal, hemodialysis, infiltration, interstitial, intra-
abdominal, intra-amniotic, intra-arterial, intra-articular, 
intrabilia r y, introbrochial, intrabursal, intracardiac, intracar-
itlaginous, intracavita r y, intracerebral, intracisternal, intrac-
orneal, intracoronal, intracoronary, intracorporus caverno-
sum, intradermal, intradiscal, intraductal, intraduodenal, 
intradural, intraepidermal, intraesophageal, intragastric, 
intragingival, intraileal, intralesional, intralymphatic, 
intramedull a r y, intrameningeal, intramuscular, intraocular, 65 
intraovarian, intrapericardial, intrapleural, intraprostatic, 
intrapulmonary, intrasinal, intrasynovial, intratendinous, 
55 tion of a drug is to administer the drug as a solution or 
suspension in oil. Injectable depot forms can also be made 
by forming microcapsule matrices o f  drugs and biodegrad-
able polymers, such as polylactide-polyglycoside. Depend-
ing on the ratio o f  drug to polymer and the composition o f  
60 the polymer, the rate o f  drug release can be controlled. 
Examples of other biodegradable polymers include poly-
orthoesters and polyanhydrides. Depot injectables can also 
be made by entrapping the drug in liposomes or microemul-
sions, which are compatible with body tissues. 
Suppositories for rectal administration of the drug can be 
prepared by mixing the drug with a suitable non-irritating 
excipient, such as cocoa butter and polyethylene glycol 
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which are solid at ordinary temperature but liquid at the 
rectal temperature and will, therefore, melt in the rectum and 
release the drug. 
Solid dosage forms for oral administration include, but 
are not limited to, capsules, tablets, pills, powders, gelcaps 
and granules. In such solid dosage forms, therapeutic agent 
may be admixed with at least one inert diluent such as 
sucrose, lactose or starch. Such dosage forms may also 
comprise additional substances other than inert diluents, 
e.g., tableting lubricants and other tableting aids such as 
magnesium stearate and microcrystalline cellulose. In the 
case o f  capsules, tablets and pills, the dosage forms may also 
comprise buffering agents. Tablets and pills can additionally 
be prepared with enteric coatings and other release-control-
ling coatings. 
Solid compositions of a similar type may also be 
employed as fillers in soft and hard-filled gelatin capsules 
using such excipients as lactose or milk sugar as well as high 
molecular weight polyethylene glycols and the like. 
The active compounds can also be in micro-encapsulated 
form with one or more excipients as noted above. The solid 
dosage forms o f  tablets, dragees, capsules, pills, and gran-
ules can be prepared with coatings and shells such as enteric 
coatings and other coatings well known in the pharmaceu-
tical formulating art. They may optionally contain opacify-
ing agents and can also be o f  a composition that they release 
the active ingredient(s) only, or preferably, in a certain part 
o f  the intestinal tract, optionally in a delayed manner. 
Examples o f  embedding compositions which can be used 
include polymeric substances and waxes. 
Dosage forms for topical or transdermal administration o f  
a compound o f  this invention further include ointments, 
pastes, creams, lotions, gels, powders, solutions, sprays, 
inhalants or patches. The active component is admixed 
under sterile conditions with a pharmaceutically acceptable 
carrier and any needed preservatives or buffers as may be 
required. Ophthalmic formulations, ear drops, eye oint-
ments, powders and solutions are also contemplated as being 
within the scope o f  this invention. 
The ointments, pastes, creams and gels may contain, in 
addition to an active compound o f  this invention, excipients 
such as animal and vegetable fats, oils, waxes, paraffins, 
starch, tragacanth, cellulose derivatives, polyethylene gly-
cols, silicones, bentonites, silicic acid, talc and zinc oxide, or 
mixtures thereof. 
Powders and sprays can contain, in addition to the active 
compounds o f  this invention, excipients such as lactose, talc, 
silicic acid, aluminum hydroxide, calcium silicates and 
polyamide powder, or mixtures o f  these substances. Sprays 
can additionally contain customary propellants, such as 
chlorofluorohydrocarbons. 
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herein by reference. Such dosage forms can be used to 
provide slow or controlled-release o f  one or more active 
ingredients using, for example, hydropropylmethyl cellu-
lose, other polymer matrices, gels, permeable membranes, 
osmotic systems, multilayer coatings, microparticles, lipo-
somes, microspheres, or a combination thereof to provide 
the desired release profile in varying proportions. Suitable 
controlled-release formulations known to those o f  ordinary 
skill in the art can be readily selected and adapted for use 
10 with therapeutic agents o f  the invention. For example, the 
invention encompasses solid oral dosage forms such as, but 
not limited to, tablets, capsules, gelcaps, and caplets that are 
formulated for controlled-release (i.e., slow release, 
15 
extended release, or sustained release). 
Advantages o f  controlled-release formulations include 
extended activity o f  the drug, reduced dosage frequency, and 
increased patient compliance. For example, controlled or 
extended release formulations can keep adequate dose levels 
constantly available inside a patient body to enhance deliv-
20 ery across the blood-brain barrier. 
Most controlled-release formulations are desig n ed to ini-
tially release an amount o f  therapeutic agent (active ingre-
dient) that promptly produces the desired therapeutic effect, 
and gradually and continually release of other amounts o f  
25 thug to maintain this level o f  therapeutic or prophylactic 
effect over an extended period o f  time. In order to maintain 
this constant level o f  drug inside the body, the drug must be 
released from the dosage form at a rate that will replace the 
amount o f  drug being metabolized and excreted from the 
30 body. Controlled-release of an active ingredient can be 
stimulated by various conditions including, but not limited 
to, pH, temperature, enzymes, water, or other physiological 
conditions or compounds. 
In some embodiments, two or more therapeutic agents 
35 may be administered in combination. The two or more 
therapeutic agents may be administered separately from one 
another, as part of a multiple dosage regimen. Alternatively, 
those agents may be part o f  a single dosage form, mixed 
together with a compound o f  this invention in a single 
40 composition. I f  administered as part of a multiple dosage 
regime, the two therapeutic agents may be submitted simul-
taneously, sequentially or within a period o f  time from one 
another normally within five hours from one another. 
As used herein, the term "combination," "combined," and 
45 related terms refers to the simultaneous or sequential admin-
istration o f  therapeutic agents in accordance with this inven-
tion. For example, a compound o f  the present invention may 
be administered with another therapeutic agent simultane-
ously or sequentially in separate unit dosage forms or 
50 together in a single unit dosage form. Accordingly, the 
present invention provides a single unit dosage form com-
prising a provided compound, an additional therapeutic 
agent, and a pharmaceutically acceptable carrier, adjuvant, 
Transdermal patches can provide controlled delivery o f  
active compound to the body. Such dosage forms can be 
made by dissolving or dispersing the compound in the 
proper medium. Absorption enhancers can also be used to 55 
increase the flux o f  the compound across the skin. The rate 
can be controlled by either providing a rate controlling 
membrane or by dispersing the compound in a polymer 
matrix or gel. 
or vehicle. 
The invention is provided in numerous embodiments and 
can be discerned, inter alia, in various examples. The 
following examples provide an illustrative but non-limiting 
description o f  the breadth and applicability o f  the invention. 
Pharmaceutical compositions described herein can be 60 
formulated for immediate release or controlled release (also 
referred to as slow, sustained or extended release). Various 
slow or extended release formulations or devices are well 
known to those of ordinary skill in the art. Examples include, 
but are not limited to, those described in U.S .  Pat. Nos. 65 
5,674,533, 5,059,595, 5,120,548, 5,073,543, 5,639,476, 
5,354,556, and 5,733,566, each of which is incorporated 
EXAMPLES 
Example 1. Neurotoxic Effect o f  PDS/TTR 
Complex 
It has been shown that examination of cell culture 
medium obtained from epithelial cells derived from 
Alzheimer's disease patients showed elevated levels o f  the 
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PDS/TTR complex compared to control cells, indicating that 
the PDS/TTR complex can be used as an effective biomarker 
for the early diagnosis of Alzheimer's disease. See, U.S. 
Application Pub. No. 20080026405, the disclosure of which 
is incorporated by reference herein. This example shows that 5 
in addition to being a biomarker for disease, the PDS/TTR 
complex is also neurotoxic. 
First of all, it was found that acrolein (an alpha, beta 
unsaturated three carbon aldehydic by-product of lipid per-
oxidation) causes normal control epithelial cells to express 10 
the PDS/TTR complex into culture medium at comparable 
levels to the epithelial cells derived from Alzheimer's dis-
ease patients. For these experiments, primary cultures of 
choroid plexus epithelial cells were established from short 
post mortem interval autopsies using established methods. 15 
AD and normal control cultures were grown to confluence in 
MEM growth medium containing 2% fetal bovine serum 
and 1% epithelial growth factor (EGF). Normal control 
cultures were switched to Opti-MEM containing N2 supple-
ment and were treated with vehicle (controls) or with 5 µM 20 
acrolein for 72 hours. Cultures from AD subjects were 
switched to N2 supplemented medium and maintained for 
72 hours. After treatment, medium was collected from each 
flask and was desalted using PD-10 columns. The eluted 
proteins were then freeze-dried, resuspended in 25 µl water 25 
and analyzed using Western blot analysis and antibodies 
specific to PDS and TTR. FIG. 1 shows exemplary results 
illustrating an Western blot analysis of the PDS/TTR com-
plex expressed in cell culture medium by control epithelial 
cells, control epithelial cells treated with acrolein, and 30 
epithelial cells derived from late stage Alzheimer's disease 
patients. As shown in FIG. 1, acrolein increased the expres-
sion of the PDS/TTR complex in control epithelial cells to 
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Therefore, PHFl immunopositivity is typically an indicator 
of the formation of late-stage neurofibrillary tangles in 
Alzheimer's disease. Thus, this experiment shows that the 
PDS/TTR complex promotes the formation of paired helical 
filaments in SY5Y neuroblastoma cells, indicating the PDS/ 
TTR that complex can promote amyloid beta peptide (A ) 
generation by H4 neuroglioma cells. 
To determine if the complex generated by epithelial 
cultures would impact inflanimatory cytokine pathways, 
cultures of human astrocytomas were plated at a density of 
2.5xl 05 cells/well and were exposed to conditioned medium 
for 24 hours. Following exposure medium was collected 
from each well and levels of inflammatory cytokines (IL-6, 
TNF-a, TGF-  and IL-6) were determined using commer-
cially available ELISAs. Results of the assays showed the 
PDS/TTR complex activated 2 inflammatory cytokine path-
ways (i.e., IL-6, TNF-a) in astrocytoma cultures (data not 
shown), indicating a role of the PDS/TTR in neuroinflam-
mation. 
In s = a ry, the experiments described in this example 
established that the PDS/TTR complex causes various bio-
chemical changes that can directly impact hallmarks of 
Alzheimer's disease. 
Example 2. Nifedipine, Nifedipine Analog Mix 
and/or T3/T4 Inhibit PDS/TTR Expression 
The assays described in Example 1 provide a tool to 
identify potential therapeutic agents that can protect neu-
ronal cells against the PDS/TTR complex. The inventors 
observed that compounds such as nifedipine (1,4-dihydro-
2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic 
acid dimethyl ester, CAS#21829-25-4 (Sig ma Aldrich)), a 
calcium channel blocker prescribed for high blood pressure; a level comparable to that in late stage AD (LAD) epithelial 
cells. 
Medium from LAD epithelial cells that contains the 
PDS/TTR complex was then used to treat cortical neurons. 
To determine if PDS/TTR complex generated by LAD 
choroid plexus epithelial cultures or normal control cultures 
treated with vehicle or with 5 µM acrolein negatively 
impacted prima ry  cortical neurons, normal control epithelial 
cultures were switched to N2 supplemented medium and 
treated with vehicle alone (controls) or with 5 µM acrolein 
for 16 hours. LAD cultures were switched to N2 medium for 
35 or nifedipine analogs such as oxidized derivative of nife-
dipine ((2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicar-
boxylic acid dimethyl ester, CAS#67035-22-7 (Sig ma 
Aldrich)) or a nitroso derivative ofnifedipine (2,6-dimethyl-
4-(2-nitrosopheny 1 )-3, 5-pyridinedicarboxy lie acid dimethy 1 
40 ester, CAS#50428-14-3 (Sigma Aldrich)), can effectively 
inhibit the expression of PDS/TTR complex in cell culture, 
individually or in combination. In addition, T3 and T4 were 
also evaluated and found to be effective in inhibiting the 
expression of PDS/TTR complex. 
Specifically, epithelial cells were treated with 5 µM acro-
lein, 5 µM acrolein plus 0.5 µM T3/0.5 µM T4, 5 µM 
acrolein plus 1 µM nifedipine mixture (nitroso-nifedipine 
55%, oxidized nifedipine 11 % and nifedipine 34% ), or 5 µM 
acrolein plus 1 µM nifedipine mixture and 0.5 µM T3/0.5 
16 hours. After treatment, medium was collected from each 45 
culture type (LAD; normal controls treated with vehicle 
alone or normal controls treated with 5 µM acrolein) and was 
added to primary rat neuron cultures (7 days in culture). 
Prima ry  cultures treated were subjected to the conditioned 
medium for 16 hours and cell viability was measured using 
MTT reduction assays. An exemplary result was shown in 
FIG. 2. As shown in FIG. 2, the survival rate for cortical 
neurons treated with LAD epithelial medium is significantly 
lower as compared to the control (FIG. 2). This experiment 
indicates that the PDS/TTR complex is itself neurotoxic. 
50 µM T4, as described in Example 1. The amount of PDS/TTR 
secreted into the culture medium by each culture was 
determined by Western blot analysis as described above. 
Exemplary data was shown in FIG. 4. As can be seen, the 
amount expressed by cells treated with acrolein plus T3/T4, 
55 acrolein plus nifedipine mixture, or acrolein plus nifedipine 
mixture and T3/T4, was significantly less than that 
expressed by cells treated only with acrolein. 
To further investigate the neurotoxic effect of the PDS/ 
TTR complex, SY5Y neuroblastoma cells were exposed to 
conditioned medium from LAD or normal control epithelial 
cells for 16 hours. Following exposure to conditioned 
medium, cells were fixed in 70% methanol/30% acetone and 
were subjected to immunohistochemistry using anti-PHF-1 
antibody. PHF-1 recognizes aberrantly phosphorylated Tau 
as observed in AD NFT (neurofibrilla ry  tangles). As shown 
in FIG. 3, close to 25% of SY5Y cells treated with LAD 
epithelial cell medium are PHF-1 positive as compared to 
about 3% ofSY5Y cells treated with control medium. Paired 
helical filaments are precursors to neurofibrilla ry  tangles. 
In addition, immunostaining was used to determine the 
PDS/TTR-positive cells and the numbers of PDS/TTR-
60 positive cells from treated and untreated cell cultures were 
counted and compared. Exemplary results were summarized 
in FIG. 5. As can be seen from FIG. 5, the number of 
PDS/TTR-positive cells in acrolein alone-treat sample is 
about 600% of the number of PDS/TTR-positive cells in 
65 untreated control. By contrast, the numbers of PDS/TTR-
positive cells in samples treated with acroline plus acrolein 
plus T3/T4, acrolein plus nifedipine mixture, or acrolein 
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plus nifedipine mixture and T3/T4 were significantly 
reduced as compared to untreated control. 
To determine if the nifedipine mix functions through 
blocking calcium channels, we evaluated the impact of the 
nifedipine mix on the calcium channels. SY5Y neuroblas- 5 
toma cultures were pretreated for 16 hours with fresh 
nifedipine or the nifedipine mix and were then switched to 
calcium free medium and loaded with 5 µM Fura-2 fluores-
cent dye. Cultures were then rinsed with calcium free 
medium and exposed to calcium containing medium and 10 
fluorescence resulting from Ca binding to Fura-2 was mea-
sured using confocal microscopy and excitation at 340 nm. 
50 to 100 cells were imaged per dish for 3 separate dishes. 
An exemplary result is shown in FIG. 6. Interestingly, as 
shown in FIG. 6, the nifedipine mix had minimal (-30%) 15 
activity as a calcium channel blocker compared to fresh 
nifedipine indicating these compounds may act through an 
alternative, novel mechanism. 
Therefore, the experiments described in this example 
indicate that nifedipine analog mix and T3/T4, alone or in 20 
combination, can effectively inhibit PDS/TTR expression in 
epithelial cells, and this effect is likely to be independent of 
calcium channels. Furthermore, T3/T4 improved the effec-
tiveness of the nifedipine analogs. 
Example 3. Nifedipine Analogs Inhibit 
Inflammatory Cytokine Production 
25 
46 
exposed to medium from epithelial cells treated with acro-
lein and combinations of nifedipine, nifedipine analogs, 
mixtures ofnifedipine analogs and T3/T4 using procedures 
described in Example 1. As shown in FIG. 9, nifedipine mix 
and nifedipine/nifedipine analogs plus T3/T4 significantly 
reduced PHF-1 levels. 
Example 6. Inhibition of A l-42 Production from 
H4 Neuroglioblastoma Cells 
In this example, the inventors used H4 neuroglioblastoma 
cells stably transfected to overexpress amyloid precursor 
protein (APP) to further investigate if nifedipine, nifedipine 
analogs ( e.g., oxidized nifedipine or nitroso-nifedipine) and/ 
or T3/T4 can inhibit the production of A l-42. H4 neuro-
glioblastoma cells stably transfected with a construct over-
expressing amyloid precursor protein (APP) secret A 1_42 
into the culture medium. These H4 cells were treated with 1 
µM fresh nifedipine, 1 µM oxidized nifedipine, 1 µM 
nitroso-nifedipine, or 0.5 µM T3/0.5 µM T4 for 16 hours. 
The A  levels in the culture medium were measured using 
ELISAs (Invitrogen). As shown in FIG. 10, treatment of 
fresh nifedipine, oxidized nifedipine, nitroso-nifedipine, or 
T3/T4 lead to significantly decreased production of A l-42. 
Furthermore, the effect of nifedipine, nifedipine analogs 
and nifedipine mix on A l-42 production from H4 cells 
were further tested with and without T3/T4. Exemplary 
results are summarized in FIG. 11. As can be seen, T3/T4 
improves the inhibitory effect of nifedipine, nifedipine ana-It was reported that inflammatory response elements 
( cytokines) are elevated in Alzheimer's disease patients. The 
inventors tested the nifedipine mix and individual analogs in 
astrocytoma cultures. Human astrocytoma cells were plated 
at 2.5xl05 cells/well in 6 well culture plates and were grown 
for 24 hours. Cultures were then switched to serum free 
Opti-MEM and treated with the nifedipine mixture and 
individual analogs for 24 hours. Three 6-well plates were 
subjected to each treatment. Following treatment, medium 
was collected from each well and levels of IL-1 , IL-6, 
TNF-a and TGF-  were measured using commercially 
available ELISAs. Exempl a r y  results are shown in FIG. 7. 
As can be seen from FIG. 7, IL-1, IL-6 and TNF-a secreted 
in the medium were sig nificantly reduced with the treatment 
of nifedipine mix or oxidized nifedipine, indicating these 
compounds have a direct positive effect on neuroinflamma-
tion. 
30 logs and nifedipine mix on A l-42 production. 
We then tested if other calcium channel blockers can 
inhibit A  1-42 generation in H4 neuroglioma cultures. 
Known calcium channel blockers such as Amilodpine, Dili-
tiazem, Felodipine, Isradipine, Nicardipine, and Nimodipine 
35 were used in this experiment. Specifically, H4 cells were 
treated with 1 µM each drug, with and without T3/T4, in 
opti-MEM (Serum free) for 16 hours and A l-42 secreted 
into medium was measured using Invitrogen ELISAs. 
Exemplary results are shown in FIG. 12. As shown in FIG. 
40 12, Nicardipine, showed a trend (p<0.10) toward a signifi-
cant decrease in A  secretion and Nimodipine led to a 
significant (p<0.05) decrease in A  formation. The other 
drugs did not significantly alter levels of A  formation. 
Combining the alternate calcium channel blockers with 
Example 4. NFD-Ll Inhibits Inflammatory 
Cytokine Production 
45 T3/T4 showed a sig nificant decrease of A  formation when 
T3/T4 were combined with Amlodipine and Dilitiazem. 
Combinations ofT3/T4 with the other drugs did not provide 
any significant decrease in A  formation. 
Using a similar procedure to that described in Example 3, 50 
NFD-Ll was tested in astrocytoma cultures. As can be seen 
from FIG. 8, IL-1, IL-6, and TNF-a secreted in the medium 
were significantly reduced with the treatment of NFD-Ll, 
indicating that NFD-Ll has a direct positive effect on 
neuroinflammation. The results shown in this example indi- 55 
cate that a lactam such as NFD-Ll can effectively inhibit 
inflammatory condition in the central nervous system. 
Example 5. Nifedipine, Nifedipine Mix and/or 
T3/T4 Reduce PHF-1 Levels 60 
As described in Example 1, SY5Y neuroblastoma cells 
exposed to medium from LAD epithelial cells that contained 
significantly higher levels of the PDS/TTR complex dis-
played significantly increased PHF-1 immunostaining as 65 
compared to those exposed to medium from untreated 
control cultures. In this experiment, SY5Y cells were 
Example 7. Inhibition of A l-42 Production from 
H4 Neuroglioblastoma Cells by NFD-Ll 
Using a procedure similar to that described in Example 6, 
NFD-Ll was tested for inhibition of A  1-42 generation in 
H4 neuroglioma cultures. As shown in FIG. 13, A  1-42 
generation is inhibited by NFD-Ll. The results shown in this 
example indicate that a lactam such as NFD-Ll can effec-
tively inhibit A l-42 production. 
Example 8. Inhibition of Beta Secretase (BACE) 
and Gannna Secretase Activity 
This surprising finding that nifedipine, nifedipine analogs 
and nifedipine mix can effectively inhibit A  1_42 peptide 
generation prompted further investigation into possible 
mechanism of A  1_42 peptide reduction. It was contemplated 
that A  1_42 production depends on the activity of beta 
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secretase (BACE), an enzyme that cleaves the amyloid 
precursor protein at the beta secretase cleavage site, and the 
gamma secretase complex composed of presenilin-1 (PS-1 ), 
nicastrin, APH-1 and PEN-2 that cleaves at the gamma 
secretase cleavage site. The inventors tested whether the 5 
inhibition of A 1_42 production in our culture model system 
was due to inhibition of BACE and/or gamma secretase 
activities. 
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were significantly decreased in mice treated with nifedipine, 
nifedipine mix plus T3/T4. BACE protein levels were sig-
nificantly decreased in mice treated with nifedipine, nife-
dipine plus T3/T4 and T3/T4 alone. In contrast, there were 
no significant differences in levels of cleaved Notch with any 
treatment (FIG. 17). 
Additionally the brains were extracted and analyzed by 
GC/MS for levels of nifedipine and its analogs. Oxidized 
nifedipine was found in all samples analyzed indicating that 
components of the mixture were passing the blood-brain 
barrier and thus available for neuronal protection. This 
experiments has shown that these derivatives possess the 
brain permeability desired for treatment of Alzheimer's 
BACE activity was measured using a fluorescent substrate 
and purified recombinant BACE as part of a commercial kit 10 
from Invitrogen. As shown in FIG. 14, nifedipine alone or in 
combination with thyroxine slightly inhibited BACE activ-
ity; however, nitroso-nifedipine alone and in combination 
with thyroxine led to significant inhibition ofBACE activity 
(FIG. 14). 15 disease. 
Examination of protein levels of BACE and individual 
components of the gamma secretase complex in H4 cultures 
treated with the nifedipine mix alone or in combination with 
T3/T4 revealed that the nifedipine mix alone significantly 
reduced levels of PS-1 andPEN-2. Levels ofBACE-1 were 20 
decreased but not significantly. However, the nifedipine mix 
plus T3/T4 sig n if icantly reduced PS-1, PEN-2, BACE-1 and 
Nicastrin. APH-1 was not affected by any treatment. Exem-
plary results were shown in FIG. 16. Protein levels were 
determined in individual cells (50-100 cells/dish; 3 dishes/ 25 
experiment) using immunohistochemistry and confocal 
microscopy and were verified in total cell homogenate using 
Western blot analysis. Antibodies specific to each protein 
were purchased from commercial vendors. 
Experiments described in this example demonstrated that 30 
nifedipine mixtures, their oxidized and nitroso derivatives, 
and/or T3/T4 directly act on the enzymes responsible for A  
production. 
Experiments described in this example demonstrated that 
nifedipine mixtures, their oxidized and nitroso derivatives, 
and/or T3/T4 reduce endogenous levels of A  1-40 peptide 
Ill VIVO. 
Example 11. Nitroso-Nifedipine Inhibits Production 
of A l-40 In Vivo 
Additional experiments were conducted to show that 
nitroso-nifedipine can effectively inhibit production of A  1-
40 in vivo. Specifically, C57/B16 mice (6 per group) were 
given IP injections of increasing concentrations of nitroso-
nifedipine in 2% DMS0/98% PEG-300 for 3 days. The 
animals were sacrificed 15 minutes following the final 
injection. Brains were quickly removed, split into hemi-
spheres, and snap frozen in liquid nitrogen. Brains were 
shipped on dry ice and maintained at -80° C. until used for 
analysis. One hemisphere of each brain was homogenized in 
diethylamine (200 mg wet weight/mL) containing complete 
Example 9. Inhibition of Beta Secretase (BACE) 
by NFD-Ll 
Using a similar procedure as described in Example 8, 
NFD-Ll was tested for inhibition of BACE activity. As 
shown in FIG. 15, NFD-Ll inhibits BACE. This example 
indicates that a lactam such as NFD-Ll can effectively 
inhibit beta secretase (BACE) activity. 
35 protease inhibitors using a Dounce homogenizer. Homoge-
nate was centrifuged at 16,000xg for 30 minutes and 50 µL 
soluble protein subjected to A l-40 quantification using a 
Covance ELISA per manufacturer's instructions. Results are 
expressed as % vehicle treated animals. Results of the 
40 analyses showed acute treatment with 35 mg/kg nitroso-
nifedipine led to a significant decrease in levels of A  1-40 
(FIG. 18). 
Example 10. Inhibition of A l-40 Production In 
Vivo 45 
Based on the in vitro data described above, the inventors 
initiated an acute exposure study in 3 month old C57-
Black-6 (C57BL/6) mice. In this study, six groups of six 
C57BL/6 mice were subjected to intraperitoneal (IP) injec- 50 
tions of vehicle (2% DMS0/98% polyethylene glycol-3000 
(PEG-3000), 25 mg/kg nifedipine or nifedipine mix, T3/T4 
(10 mg/kg T3 and 10 mg/kg T4), nifedipine mix plus T3/T4 
and nifedipine plus T3/T4 on three consecutive days. Ani-
mals were euthanatized 1 hour after the third injection. The 55 
brains and terminal serum were removed and immediately 
frozen in liquid nitrogen and stored at -80° C. until used for 
analysis. 
One hemisphere of brains was homogenized for A  1-40 
measurements (Invitrogen ELISA) and the other homog- 60 
enized for protein levels. In addition, levels of PS-1, BACE, 
cleaved Notch, an essential substrate for PS-1, Nicast, 
APH-1 were measured using Western blot analysis. As 
shown in FIG. 17, mice treated with both T3/T4 and 
nifedipine mix plus T3/T4 showed a modest (25%) but 65 
significant decrease in A  1_40 levels compared to animals 
treated with vehicle. Levels of PS-1, Nicast, and APH-1 
Thus, this example demonstrates that nitroso-nifedipine 
effectively inhibits production of A l-40 in vivo. 
Example 12. Inhibition of Orphan G-Coupled 
Receptor Protein 3 (GPCR-3) In Vitro and In Vivo 
This example was conducted to test if nifedipine, nife-
dipine mixtures, and/or T3/T4 can inhibit the orphan 
G-coupled receptor protein 3 (GPCR-3), an enzyme which 
is suggested to play a role in maintaining stability of the 
g = a  secretase complex (which, as discussed above, is 
important for cleavage of APP to form A ). 
H4 neuroglioblastoma cells were treated with 1 µM mixed 
nifedipine, 1 µM mixed nifedipine plus 0.5 µM T3/0.5 µM 
T4, 0.5 µM T3/0.5 µM T4, 1 µM freshnifedipine, 1 µM fresh 
nifedipine plus 0.5 µM T3/0.5 µM T4 for 16 hours. Levels 
ofGPCR-3 were measured using Western blot analysis using 
a GPCR-3 specific antibody. As shown in FIG. 19, nife-
dipine mixtures, fresh nifedipine, and/or T3/T4 significantly 
reduced GPCR-3 expression levels in H4 cells. 
In addition, GPCR-3 levels were determined in the 
C57BL/6 mice described above in Example 10 using West-
ern blot analysis. Exemplary results are also shown in FIG. 
19. Nifedipine mixtures and T3/T4, fresh nifedipine, and 
T3/T4 also reduced GPCR-3 expression levels in mice. 
US 9,968,574 B2 
49 
Therefore, this example demonstrated that nifedipine 
mixtures, their oxidized and nitroso derivatives, and/or 
T3/T4 reduce GPCR-3 levels in vitro and in vivo. 
To determine if the reduction of GPCR-3 levels by 
nifedipine mixtures, their oxidized and nitroso derivatives, 5 
and/or T3/T4 is through a pathway involved in blood pres-
sure regulation, we tested known blood pressure drugs such 
as atenolol, captopril, and enantopirl on H4 cells. Specifi-
cally, H4 cells were treated with 1 µM each drug, with and 
without T3/T4, in Opti-MEM (Serum free) medium for 16 
10 hours and levels of GPCR-3 were measured using confocal 
microscopy and a specific anti-GPCR-3 antibody. Exem-
plary results are shown in FIG. 20. As shown in FIG. 20, 
only captopril+T3/T4 led to a signif icant change (decrease) 
in levels of GPCR-3. This experiment indicates that the 
reduction of GPCR-3 by nifedipine mixtures, their oxidized 15 
and nitroso derivatives, and/or T3/T4 is independent of 
blood pressure pathways. 
50 
mine the effects of NFD-Ll on levels of enzymes involved 
in A  processing. As shown in FIG. 23, similar to nitroso-
nifedipine, NFD-Ll led to a signif icant decrease in BACE 
protein and a significant increase in ADAM-10. NFD-Ll 
also led to a significant decrease in PS-1 and NCT. This 
example demonstrated that treatment with lactam such as 
NFD-Ll has significant effect on levels of enzymes involved 
in A  processing. 
Example 15. Effects ofNitroso-Nifedipine on 
Levels of Enzymes Involved in A  Processing in 
Vivo 
To determine the effects of nitroso-nifedipine on levels of 
enzymes involved in A  processing in vivo, levels of A  
were quantified by ELISA and levels of proteins involved in 
A  processing were quantified by Western blot analysis for 
mice treated with vehicle or 35 mg/kg nitroso-nifedipine 
(FIG. 24). IP injections for 3 days led to a significant Example 13. Effects of Nitroso-Nifedipine on 
Levels of Enzymes Involved in A  Processing 20 decrease in A  1-40 and a signif icant decrease in presenilin-
1. The data also show that nitroso-nifedipine mediated 
inhibition of PS-1 did not decrease levels of cleaved Notch-I 
but instead led to a significant increase in levels of cleaved 
This experiment was conducted to determine effects of 
nitroso-nifedipine on levels of enzymes involved in A  
processing. Suitable concentration of nitroso-nifedipine was 
first determined based on the survival rate ofH4 cells treated 25 
with increasing concentrations of nitroso-nifedipine. Spe-
cifically, H4 neuroglioma cultures were plated at a density of 
2.5xl05 cells/well and allowed to attach overnight. Cultures 
were switched to Opti-MEM and treated for 16 hours with 
increasing concentrations of nitroso-nifedipine. Following 
treatment, MTT was added at a final concentration of 0.5 30 
mg/mL and cultures incubated for 30 minutes. Following 
MTT treatment, medium was removed and the formazan 
crystals generated by mitochondrial conversion of MTT 
were dissolved in DMSO and absorbance was measured at 
650 nm. Data are reported as mean±SEM % control MTT 35 
reduction (FIG. 21). Results of the studies suggest that H4 
cultures are more resistant to nitroso-nifedipine compared to 
nifedipine. Based on survival data, 2.5 µM nitroso-nife-
dipine was chosen for use in additional studies. 
To determine the effects of nitroso-nifedipine on levels of 40 
enzymes involved in A  processing, H4 neuroglioma cul-
tures that overexpress APP were plated at a density of 
2.5xl05 cells/dish and allowed to attach overnight. Cultures 
were switched to Opti-MEM and treated with 2.5 µMor 0.5 
µM nitroso-nifedipine alone or 2.5 µM nitroso-nifedipine+ 45 
nifedipine (0.1 and 0.01 µM) or 1 µM T3/T4. Following 
treatment, cultures were rinsed three times in PBS and fixed 
Notch-I. In addition, treatment with nitroso-nifedipine led to 
a signif icant increase in levels of ADAM-10, which func-
tions as an alpha secretase. It is contemplated that increased 
ADAM-10 levels lead to increased cleavage at the alpha 
secretase position of APP, minimizing generation of A . 
Example 16. Effects of NFD-Ll on Levels of 
Enzymes Involved in A  Processing In Vivo 
The effects of NFD-Ll on levels of enzymes involved in 
A  processing in vivo were determined using a similar 
procedure to that described in Example 15. As shown in FIG. 
25, similar to nitroso-nifedipine, IP injections of NFD-Ll 
led to a significant decrease in A  1-40 and a significant 
decrease in presenilin-1. The data also show that NFD-Ll 
mediated inhibition of PS-1 led to a significant increase in 
levels of cleaved Notch-I. In addition, treatment with NFD-
Ll led to a signif icant increase in levels of ADAM-10. Thus, 
this example demonstrated that treatment with lactam such 
as NFD-Ll has significant effect on levels of enzymes 
involved in A  processing in vivo. 
Example 17. Inhibition of Tau Phosphorylation 
In this example, we tested if nifedipine, nifedipine mix-
tures, their oxidized and nitroso derivatives, and/or T3/T4 
in 70% methanol/30% acetone for 30 minutes at -20° C. 
Cultures were then subjected to immunohistochemistry for 
BACE, PS-1, GPCR-3, nicastrin, and ADAM (the enzyme 
responsible for alpha secretase cleavage). 30 to 50 cells were 
imaged in 4-5 fields/dish (3 dishes each treatment) (FIG. 
22). Similar to results observed for nifedipine, nitroso-
nifedipine treatment led to a significant decrease in BACE 
protein. In contrast to nifedipine, nitroso-nifedipine did not 
significantly alter PS-1 or nicastrin levels. Also in contrast to 
nifedipine, nitroso-nifedipine led to a signif icant increase in 
GPCR-3. Nitroso-nifedipine also led to a significant increase 
50 can reduce phosphorylated Tau protein. Phosphorylated tau 
protein can result in the self-assembly of tangles of paired 
helical filaments and straight filaments, which are involved 
in the pathogenesis of Alzheimer's disease. 
in levels of ADAM-10 which is responsible for cleavage of 
A  at the alpha secretase site. Alpha secretase cleavage leads 
to decreased A l-42. 
Example 14. Effects of NFD-Ll on Levels of 
Enzymes Involved in A  Processing 
Using a similar procedure as described in Example 13, H4 
neuroglioma cultures were treated with NFD-Ll to deter-
Although there are multiple kinases involved in Tau 
55 phosphorylation, glycogen synthase kinase-3  (GSK-3 ) 
has received considerable attention as a major contributor to 
Tau hyperphosphorylation in AD. GSK-3  is present in 
-95% paired helical filaments identified using specific-
phospho-Tau antibodies. GSK-3 , a constitutively active 
60 kinase is inactivated by phosphorylation of Ser 9 by protein 
kinase B (Akt). Akt, a serine/threonine kinase is regulated by 
phosphatidylinositol kinase (PI3K) mediated signaling and 
is activated by phosphorylation of a regulatory threonine 
residue (Thr-308) by phosphatidylinositol dependent kinase 
65 1 (PDKl) and by phosphorylation of Ser 473 by PDKa/ 
TORC2 kinase. In addition, activation of the Akt/GSK-3  
pathway may be mediated by GCPRs coupled to Ga 12113
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heterotrimeric G proteins. Activation of Ga12 has been 
shown to stimulate RhoA and its effector Rho kinase 
(ROCK). ROCK phosphorylated at ser160 further transac-
tivates a receptor tyrosine kinase (RTK) that activates the 
PI3K signaling pathway leading to phosphorylation/activa- 5 
tion of Akt/GSK-3  (reviewed by New et al, "G protein-
coupled receptor-induced Akt activity in cellular prolifera-
tion and apoptosis," FEES J, 2007; 274:6025-36.). 
Phosphoryalted Akt increases phosphorylation and inactiva-
tion of GSK-3  therefore reducing Tau phosphorylation. 
We examined levels and the phosphorylation status of 10 
proteins involved in the tau phosphorylation pathway 
described above in the mouse brains treated with nifedipine, 
nifedipine mix and/or T3/T4 as described in Example 10. As 
shown in FIG. 26, the levels of phosphorylated ROCK 
(p-ROCK) and GSK-3  (p-GSK-3 ) were significantly 15 
increased in mice treated with nifedipine or nifedipine mix 
plus T3/T4. T3/T4 alone also significantly increased the 
level of p-GSK-3 . The total protein levels of ROCK were 
not affected by any of the treatment. The level of p-25 was 
slightly reduced in treated mice. These results indicate that 20 
nifedipine, nifedipine mix and/or T3/T4 treatment can lead 
to reduced Tau phosphorylation in vivo. 
52 
In the first study, subjects were segregated into controls, 
controls withAPOE4 (a gene linked to increased incidence 
of Alzheimer's disease), subjects on dihydropyridine based 
calcium channel blockers and subjects on dihydropyridine 
based calcium channel blockers and with APOE4. MMSE 
(Mini Mental Status Examination) test was used to measure 
cognitive function of each subject. A trajectory of the fitted 
model versus age can be determined. FIG. 29 shows exem-
plary results of the NLMIXED model ofMMSE. This model 
indicates that subjects on calcium channel blockers show a 
4 year lag in cog nitive decline relative to subjects not on 
calcium channel blockers. 
This human association study demonstrated that the use of 
dihydropyridine calcium channel blockers appears to delay 
the onset of cognitive decline, suggesting dihydropyridine 
calcium channel blockers can be used to treat neurodegen-
erative diseases such as Alzheimer's disease. 
In the second study, we conducted autopsy on a total of 8 
subjects from the neuropsychological association study. 4 
subjects were on calcium channel blockers, including nife-
dipine and 4 subjects were not on any calcium channel 
blocker. Levels ofA l-42 and A  processing enzymes such 
as PS-1, Nicas, BACE, APH-1 and PEN-2 in front lobe 
specimens of subjects were determined using standard meth-Example 18. Effects of Nifedipine and 
Nitroso-Nifedipine on Glutamate Transport 
To test the effect of nitroso-nifedipine on glutamate trans-
port, astroglioma cultures were plated at 2.5xl05 cells/well 
and allowed to attach overnight. The cultures were switched 
to Opti-MEM and treated with 2.5 µM nitroso-nifedipine for 
16 hours. Cultures were washed three times with PBS and 
fixed with 70% methanol/30% acetone at -20° C. for 30 
minutes. Following fixation, cultures were immunostained 
using antibodies specific to EAATl or EAAT2 (Glut-1), the 
major glutamate transporters. Cultures were then imaged 
using confocal microscopy and staining intensity quantified 
using Leica software. 30 to 50 cells were imaged per field 
and 5 fields were imaged per culture dish. Results of the 
analyses showed that nitroso-nifedipine led to a significant 
increase of EAAT2 but no change in EAATl (FIG. 27). 
EAAT2 has been shown to be significantly decreased in AD 
brain. Using tissue specimens from C57/B16 mice treated 
acutely for 3 days with 25 mg/kg nifedipine we subjected 20 
µg samples of protein to Western blot analysis and probed 
for EAAT2. Results of the analysis showed a significant 
increase in EAAT2 with nifedipine. Together, these data 
suggest that both nifedipine and nitroso-nifedipine lead to 
increased levels of a key glutamate transporter shown to be 
altered in AD brain. 
25 ods. Specifically, A  1-42 levels were determined using 
Invitrogen ELISAs and protein levels were determined using 
Western blot analysis and antibodies specific to each protein. 
As shown in FIG. 30, the A l-42 level was significantly 
reduced in subjects with drugs as compared to that in 
Example 19. Liver Toxicity Study 
30 subjects without drugs. Some A  processing enzymes 
including PS-1, Nicas were significantly reduced in those 
subjects with drugs as compared to those without drugs. 
Interestingly, the levels ofBACE, APH-1 and PEN-2 were 
increased in those subjects with drugs as compared to 
35 subjects without drugs. 
In addition, enzyme levels that are involved in Tau 
phosphorylation were also examined in frontal lobe speci-
mens from the subjects. As shown in FIG. 31, the levels of 
phosphorylated p-Akt, p-GSK-3  and p-ROCK were all 
40 increased in subjects with drug as compared to those in 
subjects without drug. The total protein levels of Akt, 
GSK-3  and ROCK were comparable in subjects with and 
without drug. As discussed above, activated p-Akt phospho-
rylates GSK-3 , which is then inactivated and reduces Tau 
45 phosphorylation. These results are consistent with the con-
clusion that the use of calcium channel blockers can reduce 
Tau phosphorylation, useful for treatment of Alzheimer's 
disease. 
This human association study demonstrated that the use of 
50 calcium channel blockers appears to reduce A  1-42 level 
and certain A l-42 processing enzymes, and inactivate 
enzymes involved in Tau phosphorylation in human patients, 
indicating calcium channel blockers may be effective in 
treating Alzheimer's disease. 
To determine if treatment with nitroso-nifedipine leads to 
liver toxicity, alkaline phosphatase levels were quantified in 
terminal serum samples from mice treated with increasing 55 
doses of nitroso-nifedipine using an alkaline phosphatase kit 
commonly used in clinical practice (Diagnostic Chemicals 
Limited). Results of the assays showed nitroso-nifedipine 
did not sig nif icantly increase serum alkaline phosphatase 
levels at any dose and actually led to a significant decrease 60 
in levels at a dose of35 mg/kg (FIG. 28). These data suggest 
that nitroso-nifedipine does not induce liver damage. 
Example 21. Nitroso-Nifedipine Increases Calcium 
Influx 
This experiment was conducted to determine whether or 
not nitroso-nifedipine functions as a calcium channel 
blocker. H4 neuroglioma cultures were loaded with 5 µM 
Fluo-4 AM for 30 minutes, washed three times with Locke's 
with glucose and treated with vehicle, 1 µM nifedipine or 2.5 
µM nitroso-nifedipine for 1 hour. Cells were depolarized by Example 20. Human Association Studies 
Human association studies were conducted to determine 
the impact of calcium channel blockers on human patients. 
65 addition of 40 µL 100 mM KC! and calcium levels quantified 
30 seconds following depolarization by confocal micros-
copy (n=75-100 cells/dish for 3 dishes/treatment). As 
US 9,968,574 B2 
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expected, nifedipine led to a significant decrease in Ca influx 
following depolarization. In contrast, treatment with nitroso-
nifedipine led to a sig n if icant increase in Ca influx following 
depolarization (FIG. 32). 
Therefore, this example demonstrates that, unlike nife-
dipine, nitroso-nifedipine does not function as a calcium 
channel blocker. Surprisingly, nitroso-nifedipine increases 
calcium influx. Without wishing to be bound by any theory, 
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group are considered satisfied i f  one, more than one, or all 
o f  the group members are present in, employed in, or 
otherwise relevant to a given product or process unless 
indicated to the contrary or otherwise evident from the 
context. The invention includes embodiments in which 
exactly one member o f  the group is present in, employed in, 
or otherwise relevant to a given product or process. The 
invention also includes embodiments in which more than 
it is contemplated that nitroso-nifedipine and its derivatives 
treat M C I  or Alzheimer's disease through a novel mecha- 10 
nism independent of blocking calcium channels. 
one, or all of the group members are present in, employed in, 
or otherwise relevant to a given product or process. Further-
more, it is to be understood that the invention encompasses 
Example 22. Synthesis o f  Nitroso-Nifedipine 
all variations, combinations, and permutations in which one 
or more limitations, elements, clauses, descriptive terms, 
15 etc., from one or more o f  the claims or from relevant 
portions of the description are introduced into another claim. 
For example, any claim that is dependent on another claim 
can be modified to include one or more limitations found in 
any other claim that is dependent on the same base claim. 
Photochemical synthesis was used in this example to 
synthesize nitrosonifedipine. Specifically, nifedipine (20 
mg) was dissolved in 10 mL acetonitrile in a pyrex culture 
tube, capped and photolyzed with a 250 W halogen lamp 
(3M EVW) for 30 minutes. The product was isolated by 
solvent removal on a rotary evaporator to obtain a blue- 20 
green oil (18.1 mg, 94% yield). GC/MS analysis showed 
greater than 98.5% conversion to nitrosonifedipine. A n  
exemplary result is shown in FIG. 33. 
Furthermore, where the claims recite a composition, it is to 
be understood that methods o f  using the composition for any 
o f  the purposes disclosed herein are included, and methods 
o f  making the composition according to any o f  the methods 
o f  making disclosed herein or other methods known in the 
Example 23. Synthesis o f  NFD-Ll  
Nitroso-nifedipine (10 mg, 30.5 µmo!) dissolved in 5 mL 
ethanol was mixed with glutathione (93 mg, 305 µmo!) 
dissolved in 5 mL water and allowed to react at 37 ° C .  for 
25 art are included, unless otherwise indicated or unless it 
would be evident to one o f  ordinary skill in the art that a 
contradiction or inconsistency would arise. In addition, the 
invention encompasses compositions made according to any 
o f  the methods for preparing compositions disclosed herein. 
2 hours. After 2 hours, water was added and the product was 30 
extracted with ethyl acetate. The solvent was removed in a 
rotary evaporator to give NFD-Ll  as a white solid in about 
85% yield (>95% purity). A n  exemplary mass spectrum is 
shown in FIG. 34. 
Where elements are presented as lists, e.g., in Markush 
group format, it is to be understood that each subg roup of the 
elements is also disclosed, and any element(s) can be 
removed from the group. It is also noted that the term 
"comprising" is intended to be open and permits the inclu-
Example 24. Treatment o f  Human Patients 
A human patient determined to have M C I  based on an 
M M S E  score is given nitroso-nifedipine at a dosage o f  1000 
mg per day. Nitroso-nifedipine is given as tablets for oral 
administration by patient three times daily. 
Another human patient determined to have early stage 
Alzheimer's disease (EAD) based on a C D R  score is given 
nitroso-nifedipine at a dosage o f  800 mg per day. Nitroso-
nifedipine is given as tablets for oral administration by 
patient three times daily. 
35 sion o f  additional elements or steps. It should be understood 
that, in general, where the invention, or aspects o f  the 
invention, is/are referred to as comprising particular ele-
ments, features, steps, etc., certain embodiments of the 
invention or aspects o f  the invention consist, or consist 
40 essentially of, such elements, features, steps, etc. For pur-
poses o f  simplicity those embodiments have not been spe-
cifically set forth in haec verba herein. Thus for each 
embodiment o f  the invention that comprises one or more 
elements, features, steps, etc., the invention also provides 
45 embodiments that consist or consist essentially o f  those 
elements, features, steps, etc. 
A human patient determined to have M C I  based on the 
level o f  PDS/TTR complex in a fluid sample obtained from 
the patient is given nitroso-nifedipine at a dosage o f  1000 
mg per day. Nitroso-nifedipine is given as tablets for oral 50 
administration by patient four times daily. 
Where ranges are given, endpoints are included. Further-
more, it is to be understood that unless otherwise indicated 
or otherwise evident from the context and/or the understand-
ing o f  one o f  ordinary skill in the art, values that are 
expressed as ranges can assume any specific value within the 
stated ranges in different embodiments o f  the invention, to 
EQUIVALENTS 
The foregoing has been a description of certain non-
limiting embodiments of the invention. Those skilled in the 
art will recognize, or be able to ascertain using no more than 
routine experimentation, many equivalents to the specific 
embodiments o f  the invention described herein. Those o f  
ordinary skill in the art will appreciate that various changes 
and modifications to this description may be made without 
departing from the spirit or scope o f  the present invention, 
as defined in the following claims. 
the tenth o f  the unit o f  the lower limit of the range, unless 
the context clearly dictates otherwise. It is also to be 
55 understood that unless otherwise indicated or otherwise 
evident from the context and/or the understanding o f  one o f  
ordinary skill in the art, values expressed as ranges can 
assume any subrange within the given range, wherein the 
endpoints o f  the subrange are expressed to the same degree 
60 o f  accuracy as the tenth of the unit of the lower limit of the 
range. 
In the claims articles such as "a,", "an" and "the" may 
mean one or more than one unless indicated to the contrary 65 
or otherwise evident from the context. Claims or descrip-
tions that include "or" between one or more members o f  a 
In addition, it is to be understood that any particular 
embodiment of the present invention may be explicitly 
excluded from any one or more o f  the claims. Any embodi-
ment, element, feature, application, or aspect of the compo-
sitions and/or methods of the invention can be excluded 
from any one or more claims. For purposes o f  brevity, all o f  
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the embodiments in which one or more elements, features, 
purposes, or aspects is excluded are not set forth explicitly 
herein. 
INCORPORATION OF REFERENCES 
All publications and patent documents cited in this appli-
cation are incorporated by reference in their entirety to the 
same extent as if the contents of each individual publication 
or patent document were incorporated herein. 
What is claimed is: 
1. A method for treating Mild Cognitive Impairment 
(MCI) or Alzheimer's disease in a human subject, the 
method comprising 
administering to a subject who is suffering from or 
susceptible to Mild Cognitive Impairment (MCI) or 
Alzheimer's disease a therapeutically effective amount 
of a lactam such that at least one symptom or feature 
associated with Mild Cognitive Impairment (MCI) or 
Alzheimer's disease is reduced in abundance, intensity, 
severity, or frequency, or has delayed onset; and 
wherein the lactam is NFD-Ll, 
(le) 
2. The method of claim 1, wherein the at least one 
symptom or feature is the production of amyloid beta 
protein. 
56 
at least one second, different protein selected from a 
transthyretin, prostaglandin-H2 D-isomerase, beta-2-
microglobulin, cystatin C, superoxide dismutase [ C u -
Zn], plasma retinal-binding protein, phosphatidyletha-
nolamine-binding protein, carbonic anhydrase 2, and/or 
serotransferrin protein. 
6. The method of claim 5, wherein the biomarker com-
prises prostaglandin-D2-synthase and transthyretin (PDS/ 
TTR complex). 
10 7. The method of claim 1, wherein the subject has an abnormal level of a biomarker as compared to a control, 
wherein the biomarker comprises one or more of (i) beta 
amyloid 40 (A 40), (ii) beta amyloid 42 (A 42), (iii) the 
ratio of A 40 to A 42, and (iv) the ratio of phosphorylated 
15 
tau to total tau. 
8. The method of claim 1, wherein the subject has a test 
score indicative of cognitive impairment. 
9. The method of claim 8, wherein the test score is an 
MMSE (Mini Mental Status Examination) score. 
10. The method of claim 9, wherein the MMSE score 
20 ranges from 21-26. 
25 
11. The method of claim 8, wherein the test score is a
clinical dementia rating (CDR) score. 
12. The method of claim 11, wherein the CDR score is 0.5 
or 1. 
13. The method of claim 1, further comprising adminis-
tering a therapeutic amount of nitroso-nifedipine to the 
subject. 
14. The method of claim 1, further comprising adminis-
tering a mixture of nitrosonifedipine and oxidized nifedipine 
30 to the subject. 
35 
15. The method of claim 14, wherein the mixture further 
comprises triiodothyronine (T3) and thyroxine (T4). 
16. The method of claim 14, wherein the mixture further 
comprises nifedipine. 
17. The method of claim 16, wherein the mixture com-
prises 55% nitroso-nifedipine, 11 % oxidized nifedipine, and 
34% nifedipine. 
18. The method of claim 16, wherein the mixture further 
comprises triiodothyronine (T3) and thyroxine (T4). 
19. The method of claim 13, wherein the therapeutically 
effective amount of nitrosonifedipine ranges from about 10 
mg to about 2.5 g per dose. 
3. The method of claim 1, wherein the at least one 
40 symptom or feature is gamma-secretase activity, and 
wherein the gamma-secretase activity is reduced by inhib-
iting orphan G-coupled receptor 3 (GPCR-3) activity. 
20. The method of claim 1, further comprising adminis-
tering a mixture oftriiodothyronine (T3) and thyroxine (T4) 
45 to the subject. 
4. The method of claim 1, wherein the at least one 
symptom or feature is phosphorylated tau protein in the 
brain. 
5. The method of claim 1, wherein the subject has an 
abnormal level of a biomarker as compared to a control, 
wherein the biomarker comprises: 
at least one of a transthyretin protein and/or a prostaglan-
din-H2 D-isomerase protein, and 
21. The method of claim 20, wherein the mixture further 
comprises nifedipine. 
22. The method of claim 1, wherein the lactam does not 
function as a calcium channel blocker. 
* * * * *
